<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2207245628
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Trisuva
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TREPROSTINIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous, Subcutaneous
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        12537.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Lyocontract GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Lyocontract GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 467]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Thimar Aljazirah Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AOP Orphan Pharmaceuticals GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AC21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Trisuva is</strong></p><p>The active ingredient of Trisuva is treprostinil.</p><p>Treprostinil belongs to a group of medicines which work in a similar way to the naturally occurring prostacyclins. Prostacyclins are hormone-like substances which reduce blood pressure by relaxing blood vessels, causing them to widen, which allows the blood to flow more easily. Prostacyclins can also have an influence on preventing blood from clotting.</p><p>&nbsp;</p><p><strong>What Trisuva is used for</strong></p><p>Trisuva is used to treat idiopathic (without any known cause) or acquired pulmonary arterial hypertension (PAH) in patients with moderately severe symptoms. Pulmonary arterial hypertension is a condition where your blood pressure is too high in the blood vessels between the heart and the lungs, causing shortness of breath, dizziness, tiredness, fainting, palpitations or abnormal heartbeat, dry cough, chest pain and swollen ankles or legs.</p><p>&nbsp;</p><p>Trisuva is initially administered as a continuous subcutaneous (under the skin) infusion. Some patients may be unable to tolerate this because of local site pain and swelling. Your doctor will decide whether Trisuva can be administered by continuous intravenous (directly into a vein) infusion instead.. This involves the insertion of a central venous catheter that is connected to an external pump or, depending on your condition, a pump surgically implanted under the skin of your belly. Your doctor will decide what is the best option for you.</p><p>&nbsp;</p><p><strong>How Trisuva works</strong></p><p>Trisuva lowers blood pressure within the pulmonary artery by improving blood flow and reducing the amount of work for the heart. Improved blood flow leads to an improved supply of oxygen to the body and reduced strain on the heart, causing it to function more effectively. Trisuva improves the symptoms associated with PAH and the ability to exercise in patients who are limited in terms of activity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2. What you need to know before you use Trisuva</strong></p><p><strong>Do not use Trisuva:</strong></p><p>- if you are allergic to treprostinil or any of the other ingredients of this medicine (listed in section 6).</p><p>- if you have been diagnosed with a disease called &ldquo;pulmonary veno-occlusive disease&rdquo;. This is a disease in which the blood vessels that carry blood through your lungs become swollen and clogged resulting in a higher pressure in the blood vessels between the heart and the lungs.</p><p>&nbsp;</p><p>- if you have severe liver disease</p><p>- if you have a heart problem, for example:</p><p>&bull; a heart attack (myocardial infarction) within the last six months</p><p>&bull; severe changes in heart rate</p><p>&bull; severe coronary heart disease or unstable angina</p><p>&bull; a heart defect has been diagnosed, such as a faulty heart valve that causes the heart to work poorly</p><p>&bull; any disease of the heart which is not being treated or not under close medical observation</p><p>- if you are at a specific high risk of bleeding &ndash; for example active stomach ulcers, injuries or other bleeding conditions</p><p>- if you have had a stroke within the last 3 months, or any other interruption of blood supply to the brain</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Please talk to your doctor before using Trisuva.</p><p><em>Talk to your doctor before using Trisuva if you:</em></p><p>- suffer from any liver disease</p><p>-</p><p>- have been advised that you are medically obese (BMI greater than 30 kg/m2)</p><p>- have HIV (Human Immunodeficiency Virus) infection</p><p>- have high blood pressure in your liver veins (portal hypertension)</p><p>- have a birth defect in your heart which affects the way your blood flows through it</p><p>-</p><p><em>During your treatment with Trisuva, tell your doctor:</em></p><p>- if your blood pressure decreases (hypotension)</p><p>- if you experience a rapid increase in breathing difficulties or persistent cough (this can be related to</p><p>congestion in the lungs or asthma or other condition), consult your doctor immediately.</p><p>- if you have excessive bleeding as treprostinil may increase the risk, by preventing your blood from clotting</p><p>- if you develop a fever whilst receiving intravenous treprostinil or the intravenous infusion site becomes red, swollen and / or painful to the touch, as this could be a sign of infection</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Other medicines and Trisuva</strong></p><p>Tell your doctor if you are taking/using, have recently taken/used or might take/use any other medicines.</p><p>Please tell your doctor if you are taking:</p><p>- medicines used to treat high blood pressure (antihypertensive drugs or other vasodilators)</p><p>- drugs used to increase the rate of urination (diuretics) including furosemide</p><p>- medicines that stop blood clotting (anticoagulants) such as warfarin, heparin or nitric oxide-based products</p><p>- any non-steroidal anti-inflammatory (NSAID) drugs (e.g. acetylsalicylic acid, ibuprofen)</p><p>- medicines that may increase or decrease the effect of treprostinil (e.g. gemfibrozil, rifampicin, trimethoprim, deferasirox, phenytoin, carbamazepine, phenobarbital, St. John&#39;s wort) as your doctor may need to adjust your dose of Trisuva</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Trisuva is not recommended if you are pregnant, planning to become pregnant, or think that you might be pregnant, unless considered essential by your doctor. The safety of this medicine for use during pregnancy has not been established.</p><p>Contraception is strongly recommended during Trisuva treatment.</p><p>&nbsp;</p><p>Trisuva is not recommended for use while breast-feeding, because it is not known whether this medicine passes into breast milk.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Caution! This medicine may impair your ability to react or drive</p><p>&nbsp;</p><p>Trisuva may induce low blood pressure with dizziness or fainting. In such a case do not drive or operate machinery and ask your doctor for advice.</p><p>&nbsp;</p><p><strong>Trisuva contains sodium</strong></p><p>Trisuva, 1 mg/ml contains a maximum of 36.8 mg sodium (main component of cooking/table salt) in each vial.</p><p>&nbsp;</p><p>This is equivalent to 1.8 % of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p>Trisuva, 2.5 mg/ml contains a maximum of 37.3 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 1.9 % of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p>Trisuva, 5 mg/ml contains a maximum of 39.1 mg sodium (main component of cooking/table salt) in each vial.</p><p>&nbsp;</p><p>This is equivalent to 2.0 % of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p>Trisuva, 10 mg/ml contains a maximum of 37.4 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 1.9 % of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor if you are not sure.</p><p>&nbsp;</p><p>Trisuva is administered as a continuous infusion, either:</p><p>- subcutaneously (under the skin) via a small tube (cannula) which is located in your abdomen or thigh;</p><p>or,</p><p>- intravenously via a tube (catheter) that is usually located in your neck, chest or groin.</p><p>&nbsp;</p><p>In both cases, Trisuva is pushed through the tubing by a portable pump placed outside of your body (external).</p><p>&nbsp;</p><p>Before you leave the hospital or clinic, your doctor will tell you how to prepare Trisuva and at what rate the pump should deliver your treprostinil..</p><p>&nbsp;</p><p>Flushing of the infusion line whilst connected may cause accidental overdose.</p><p>Alternatively, Trisuva can be administered intravenously via an implantable infusion pump usually surgically inserted under the skin of your belly (abdomen). In this case, the pump and tubing are both fully inside your body (internal), and you will have to attend the hospital or clinic periodically (e.g. each 4 weeks) in order to get the internal reservoir refilled.</p><p>&nbsp;</p><p>In any case, information on how to use the pump correctly and what to do if it stops working should also be given to you. The information should also tell you who to contact in an emergency.</p><p>&nbsp;</p><p>Trisuva is diluted only when administered intravenously:</p><p>For intravenous infusion <strong><u>with external portable pump</u></strong>: You must dilute your treprostinil solution with either sterile Water for Injection or 0.9% Sodium Chloride for Injection (as provided by your doctor)</p><p><strong><u>For continuous intravenous infusion with implantable infusion pump:</u></strong><strong> </strong>You must attend the hospital or clinic periodically (e.g. each 4 weeks), where health care professionals should dilute your Treprostinil solution with 0.9 % Sodium Chloride for Injection and refill the internal reservoir.</p><p>&nbsp;</p><p><strong>Adult patients</strong></p><p>Trisuva is available as 1 mg/ml, 2.5 mg/ml, 5 mg/ml or 10 mg/ml solution for infusion. Your doctor will determine the infusion rate and dose appropriate for your condition.</p><p>&nbsp;</p><p><strong>Overweight patients</strong></p><p>If you are overweight (weigh 30% or more than your ideal body weight) your doctor will determine the initial and subsequent doses based on your ideal body weight. Please also refer to Section 2, &ldquo;Warnings and precautions&rdquo;.</p><p>&nbsp;</p><p><strong>Elderly patients</strong></p><p>Your doctor will determine the infusion rate and dose appropriate for your condition.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>The safety and effectiveness of Trisuva in children and adolescents under the age of 18 years is not proven.</p><p><u>Dosage adjustment</u></p><p>The infusion rate can be reduced or increased on an individual basis under medical supervision only.</p><p>The aim of adjusting the infusion rate is to establish an effective maintenance rate which improves symptoms of PAH while minimising any undesirable effects.</p><p>&nbsp;</p><p>If your symptoms increase or if you need complete rest, or are confined to your bed or chair, or if any physical activity brings on discomfort and your symptoms occur at rest, do not increase your dose without medical advice. This medicine may no longer be sufficient to treat your disease and another treatment may be required.</p><p>&nbsp;</p><p><strong>How can blood stream infections during treatment with intravenous Trisuva be prevented?</strong></p><p>As with any long-term intravenous treatment, there is a risk of getting blood stream infections. Your doctor will train you on how to avoid this.</p><p>&nbsp;</p><p><strong>If you use more Trisuva than you should</strong></p><p>If you accidentally overdose on this medicine, you may experience nausea, vomiting, diarrhoea, low blood pressure (dizziness, light-headedness or fainting), skin flushes and/or headaches.</p><p>If any of these effects become severe then you should contact your doctor or hospital immediately. Your doctor may reduce or discontinue the infusion until your symptoms have disappeared. Trisuva solution for infusion will then be reintroduced at a dose level recommended by your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>If you stop using Trisuva</strong></p><p>Always use Trisuva as directed by your doctor or medical specialist. Do not stop using Trisuva unless your doctor has advised you to.</p><p>&nbsp;</p><p>Abrupt withdrawal or sudden reductions in the dose of treprostinil may cause the pulmonary arterial hypertension to return with the potential for rapid and severe deterioration in your condition.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or medical specialist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><u>Very common (may affect more than 1 in 10 people)</u></p><p>&bull; widening of blood vessels with flushing of the skin, feeling hot</p><p>&bull; pain or tenderness around the infusion site</p><p>&bull; skin discolouration or bruising around the infusion site</p><p>&bull; headaches</p><p>&bull; skin rashes</p><p>&bull; nausea</p><p>&bull; diarrhoea</p><p>&bull; jaw pain</p><p>&nbsp;</p><p><u>Common (may affect up to 1 in 10 people)</u></p><p>&bull; dizziness</p><p>&bull; vomiting</p><p>&bull; light-headedness or fainting due to low blood pressure</p><p>&bull; itching or redness of the skin</p><p>&bull; muscle pain, joint pain</p><p>&bull; swelling of feet, ankles, legs or fluid retention</p><p>&bull; bleeding episodes such as nose bleeds, coughing up blood, blood in the urine, bleeding from the gums, blood in the faeces</p><p>&bull; pain in the arms and/or legs</p><p>&nbsp;</p><p><u>Other possible side effects (frequency cannot be estimated from the available data)</u></p><p>&bull; infection at the infusion site</p><p>&bull; abscess at the infusion site</p><p>&bull; a decrease of blood clotting cells (platelets) in the blood (thrombocytopaenia)</p><p>&bull; bleeding at the infusion site</p><p>&bull; bone pain</p><p>&bull; skin rashes with discolouration or raised bumps</p><p>&bull; tissue infection under the skin (cellulitis)</p><p>&bull;</p><p>&bull; cardiac insufficiency with high volume of blood pumped by the heart per period of time, resulting in shortness of breath, fatigue, swelling of the legs and abdomen, and persistent</p><p>coughing (high-output-heart failure)</p><p>&nbsp;</p><p><u>Additional side effects associated with the intravenous route of administration (frequency cannot be estimated from the available data)</u></p><p>&bull; inflammation of the vein (thrombophlebitis)</p><p>&bull; blood stream bacterial infection (bacteraemia)* (refer to section 3)</p><p>&bull; septicaemia (severe blood bacterial infection)</p><p>&nbsp;</p><p>* life-threatening or fatal cases of blood stream bacterial infection have been reported</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or medical specialist. This includes any possible side effects not listed in this leaflet</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date that is stated on the carton and vial after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not use this medicine if you notice any damage to the vial, discolouration or other signs of deterioration.</p><p>&nbsp;</p><p>After first opening a Trisuva vial must be used or discarded within 30 days and must be stored below 30&deg;C.</p><p>&nbsp;</p><p>During continuous subcutaneous infusion, a single reservoir (syringe) of undiluted Trisuva must be used within 14 days.</p><p>&nbsp;</p><p>During continuous intravenous infusion, a single reservoir (syringe) of diluted Trisuva must be used within 24 hours.</p><p>&nbsp;</p><p>During continuous intravenous infusion using implantable infusion pumps, diluted Trisuva introduced in the reservoir of the pump must be used within 30 days maximum. The health care professional will tell you the duration of the interval until the next refill of the reservoir</p><p>Any remaining diluted solution should be discarded.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is treprostinil</p><p>1 ml solution for infusion contains 1 mg, 2.5 mg, 5 mg, or10 mg (as treprostinil sodium), respectively.</p><p>- The other ingredients are:</p><p>Metacresol, sodium citrate (dihydrate), sodium chloride, hydrochloric acid, sodium hydroxide, and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Trisuva is a clear colourless to slightly yellow solution free from visible particles, available in a clear glass vial sealed with a rubber stopper and a colour coded aluminium cap:
• Trisuva 1 mg/ml solution for infusion has a yellow aluminium cap.
• Trisuva 2.5 mg/ml solution for infusion has a blue aluminium cap.
• Trisuva 5 mg/ml solution for infusion has a green aluminium cap.
• Trisuva 10 mg/ml solution for infusion has a magenta-coloured aluminium cap.
Each carton contains one 10 ml vial of solution for infusion.



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Batch Release Manufacturer</strong></p><p>AOP Orphan Pharmaceuticals GmbH</p><p>Leopold-Ungar-Platz 2</p><p>1190 Vienna, Austria</p><p><strong>Manufacturing Site</strong></p><p>&nbsp;</p><p>Lyocontract GmbH</p><p>Pulverwiese 1, Ilsenburg, Germany</p><p>This leaflet was last revised in September 2022.</p><p>For reporting side effects that may happen, please contact the following addresses:</p><p><strong>&bull; Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-Mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p><p><strong>&bull; United Arab Emirates:</strong></p><p>Pharmacovigilance &amp; Medical Device section</p><p>P. O. Box: 1853, Tel: 80011111</p><p>E-Mail: pv@mohap.gov.ae</p><p>Drug Department</p><p>Ministry of Health &amp; Prevention</p><p>Dubai, UAE</p><p><strong>&bull; Sultanate of Oman:</strong></p><p>Department of Pharmacovigilance &amp; Drug Information</p><p>Directorate General of Pharmaceutical Affairs &amp; Drug Control</p><p>Ministry of Health, Sultanate of Oman</p><p>Telephone: 0096822357686/0096822357687</p><p>Fax: 0096822358489</p><p>E-Mail: pharma-vigil@moh.gov.om</p><p>Website: www.moh.gov.om</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p><p><strong>This is a Medicament</strong></p><p>- Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you</p><p>- Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>- The doctor and the pharmacist are the experts in medicines, their benefits and risks.</p><p>- Do not by yourself interrupt the period of treatment prescribed for you.</p><p>- Do not repeat the same prescription without consulting your doctor.</p><p>Keep all medicaments out of reach of children</p><p>&nbsp;</p><p>Council of Arab Health Ministers - Union of Arab Pharmacists</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09/ 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما</strong><strong> </strong><strong>هو</strong><strong> </strong><strong>تريسوفا</strong></p><p dir="RTL">المادة الفعالة في تریسوفا ھي تريبروستينيل، كونھا عامل مضاد للتخثر.</p><p dir="RTL">ینتمي تریبروستینیل إلى مجموعة من الأدویة التي تعمل بطریقة مشابھة للبروستاسایكلینات التي تتشكل بشكل طبیعي.</p><p dir="RTL">البروستاسایكلینات ھي مواد شبیھة بالھرمونات تقلل من ضغط الدم عن طریق إرخاء الأوعیة الدمویة، مما یؤدي إلى اتساعھا،</p><p dir="RTL">مما یسمح للدم بالتدفق بسھولة أكبر. یمكن أن یكون للبروستاسایكلینات أیضًا تأثیر على منع تخثر الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>تریسوفا</strong></p><p dir="RTL">یستخدم تریسوفا لعلاج ارتفاع ضغط الدم الشریاني مجھول السبب (بدون أي سبب معروف) أو المكتسب (PAH )في المرضى البالغین الذین یعانون من أعراض معتدلة الشدة. ارتفاع ضغط الدم الشریاني الرئوي ھو حالة یكون فيھا ضغط الدم مرتفعاً جداً في الأوعیة الدمویة بین القلب والرئتین، مما یتسبب في ضیق التنفس، الدوخة، التعب، الإغماء، الخفقان أو عدم انتظام ضربات القلب، السعال الجاف، ألم الصدر، وتورم الكاحلین أو الساقین.</p><p dir="RTL">يتم إعطاء تریسوفا في البدایة على شكل تسریب مستمر (تحت الجلد) قد یكون بعض المرضى غير قادرين على تحمل ھذا بسبب الألم والتورم الموضعي. سیقرر طبیبك ما إذا كان یمكن إعطاء تریسوفا عن طریق التسریب المستمر في الوری (مباشرة في الورید) بدلا من ذلك. سيتطلب ذلك إدخال مدخل وریدي مركزي (قسطرة) یقع عادة في رقبتك أو صدرك أو فخذك.</p><p dir="RTL">یجب استخدام تریسوفا حسب إرشادات طبیبك، سوف یقوم طبیبك بمراقبتك بشكل دوري بعد عدة أیام من بدء العلاج بتریبروستینیل. اتصل بطبیبك فورا في حال تدھور حالتك السریریة.</p><p dir="RTL"><strong>كيف</strong><strong> </strong><strong>يعمل</strong><strong> </strong><strong>تريسوفا</strong></p><p dir="RTL">تريسوفا يخفض ضغط الدم داخل الشریان الرئوي عن طریق تحسین تدفق الدم وتقلیل كمیة عمل القلب. یؤدي تحسین تدفق الدم إلى تحسین إمداد الجسم بالأكسجين وتقلیل الضغط على القلب، مما یجعلھ یعمل بشكل أكثر فعالیة. یعمل تريسوفا على تحسین الأعراض المرتبطة بارتفاع الضغط الرئوي الشرياني والقدرة على ممارسة الرياضة في المرضى الذین يعانون من محدودية النشاط.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا</strong><strong> </strong><strong>تستخدم</strong><strong> </strong><strong>تریسوفا</strong></p><p dir="RTL">- &nbsp;إذا كنت تعاني من حساسیة تجاه تریسوفا أو تجاه أي مكون من الم كونات الأخرى بھذا الدوَّاء (المدرجة في قسم:6)</p><p dir="RTL">- &nbsp;إذا تم تشخیصك بمرض یسمى &quot;مرض انسداد الورید الرئوي&quot;. ھذا مرض تتورم فیھ الأوعیة الدمویة التي تنقل الدم عبر رئتیك وتنسد مما یؤدي إلى ارتفاع ضغط الأوعیة الدمویة بین القلب والرئتین.</p><p dir="RTL">- إذا كان لدیك مرض كبدي حاد</p><p dir="RTL">-إذا كنت تعاني من مشكلة في القلب ، على سبیل المثال:</p><p dir="RTL">&bull;نوبة قلبیة (احتشاء عضلة القلب) خلال الأشھر الستة الماضیة</p><p dir="RTL">&bull;تغیرات شدیدة في معدل ضربات القلب</p><p dir="RTL">&bull;أمراض القلب التاجیة الشدیدة أو الذبحة الصدریة غیر المستقرة</p><p dir="RTL">&bull;تم تشخیص عیب في القلب ، مثل خلل في صمام القلب یؤدي إلى ضعف عمل القلب</p><p dir="RTL">&bull;أي مرض في القلب لا یعالج أو لا یخضع للمراقبة الطبیة الدقیقة</p><p dir="RTL">&nbsp;</p><p dir="RTL">-إذا كنت معرضًا لخطر كبیر من حدوث نزیف - على سبیل المثال قرحة معدة نشطة أو إصابات أو حالات نزیف أخرى</p><p dir="RTL">- إذا أصبت بسكتة دماغیة خلال الأشھر الثلاثة الماضیة ، أو أي انقطاع آخر في إمداد الدماغ بالدم</p><p dir="RTL">إذا كنتي حاملا او مرضع ا أو تعتقدین بأنك حامل أو تخططین للحمل، خذي استشارة طبیبك أو الصیدلي قبل استخدام ھذا الدواء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذیرات</strong><strong> </strong><strong>والاحتیاطات</strong></p><p dir="RTL">یرجى التحدث مع طبیبك قبل استخدام تریسوفا</p><p dir="RTL">تحدث إلى طبیبك قبل استخدام تریسوفا:</p><p dir="RTL">-إذا كنت تعاني من أي مرض كبدي</p><p dir="RTL">-إذا كنت تعاني من مرض الكلى</p><p dir="RTL">( -إذا تم إخطارك بأنك تعاني من السمنة الطبیة (مؤشر كتلة الجسم أكبر من 30 كجم / م 2)</p><p dir="RTL">-إذا كنت مصاب بعدوى فیروس نقص المناعة البشریة (فیروس نقص المناعة البشریة)</p><p dir="RTL">- إذا كان لدیك ارتفاع في ضغط الدم في أوردة الكبد (ارتفاع ضغط الدم البابي )</p><p dir="RTL">-إذا كان لدیك عیب خلقي في قلبك مما یؤثر على طریقة تدفق الدم من خلالھ</p><p dir="RTL">-إذا كنت تتبع نظامًا غذائیاً منخفض الصودیوم</p><p dir="RTL">أثناء علاجك باستخدام تریسوفا ، أخبر طبیبك:</p><p dir="RTL">-إذا انخفض ضغط الدم لدیك (انخفاض ضغط الدم).</p><p dir="RTL">-إذا كنت تعاني من ارتفاع مفاجئ في صعوبات التنفس أو السعال المستمر (یمكن أن یكون ذلك بسبب احتقان في الرئتین أو الربو أو أي حالة أخرى) ، استشر طبیبك على الفور .</p><p dir="RTL">-إذا كان لدیك نزیف مفرط لأن تریبروستینیل قد یزید الخطورة عن طریق منع الدم من التخثر</p><p dir="RTL">- إذا أصبت بالحمى أثناء تلقي تریبروستینیل في الورید أو أصبح موضع التسریب في الورید أحمر أو منتفخًا و / أو مؤلمًا عند اللمس، لأن ھذا قد یكون علامة على الإصابة بعدوى .</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>والمراھقین</strong></p><p dir="RTL">لا تعطي ھذا الدواء للأطفال بین عمر 0 ل 18 عام بسبب توفر بیانات محدودة للأطفال والمراھقین.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تریسوفا</strong><strong> </strong><strong>والأدویة</strong><strong> </strong><strong>الأخرى</strong></p><p dir="RTL">أخبر طبیبك إذا كنت تتناول / تستخدم، أو تناولت / استخدمت مؤخرًا أو قد تتناول / تستخدم أي أدویة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبیبك إذا كنت حالیا تأخذ أي من التالي:</p><p dir="RTL">-الأدویة المستخدمة لعلاج ارتفاع ضغط الدم (الأدویة الخافضة للضغط أو موسعات الأوعیة الأخرى)</p><p dir="RTL">-الأدویة المستخدمة لزیادة معدل التبول (مدرات البول) بما في ذلك فوروسیمید</p><p dir="RTL">-الأدویة التي توقف الدم(مضادات التخثر) مثل الوارفارین ، الھیبارین أو المنتجات القائمة على أكسید النیتریك</p><p dir="RTL">-أي مضادات التھاب غیر ستیروئیدیة ( مثل حمض أسیتیل السالیسیلیك ، إیبوبروفین)</p><p dir="RTL">- الأدویة التي قد تزید أو تقلل من تأثیر تریبروستینیل (مثل جیمفیبروزیل، ریفامبیسین ، تریمیثوبریم ، دیفیراسیروكس ، فینیتوین</p><p dir="RTL">، كاربامازیبین ، فینوباربیتال ، نبتة سانت جون) حیث قد یحتاج طبیبك لتعدیل جرعتك من تریسوفا.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والارضاع</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعاً، أو تعتقدین أنكِ قد تكونین حاملًا أو تخططین لذلك، فاستشیري طبیبك أو الصیدلي الخاص بك قبل تناوُل ھذا الدوَّاء .</p><p dir="RTL">لا ینصح باستخدا م تریسوفا إذا كنتِ حاملا أو تخططین للحمل أو تعتقدین بأنك حامل ، إلا إذا اعتبر طبیبك ذلك ضروریاً. لم یتم التأكد من سلامة ھذا الدواء أثناء الحمل.</p><p dir="RTL">یوصى بشدة باستخدام موانع الحمل أثناء العلاج تریسوفا.</p><p dir="RTL">لا ینصح باستخدا م تريسوفا أثناء الرضاعة الطبیعیة، لأنه من غير المعروف ما إذا كان ھذا الدواء ینتقل إلى حلیب الثد ي.</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>واستعمال</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">احذر! قد یضعف ھذا الدواء قدرتك على الاستجابة أو القياد ة</p><p dir="RTL">قد یسبب تریسوفا انخفاض ضغط الدم مع الدوار أو الإغماء. في مثل ھذه الحالة لا تقود السیارة أو تشغل الآلات واطلب من طبیبك النصیحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي</strong><strong> </strong><strong>تریسوفا</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الصودیوم</strong></p><p dir="RTL">تریسوفا، ٥ ملغ / مل تحتوي على &nbsp;۳۹.۱ملغ صودیوم كحد أقصى ( مكون رئیسي في الطبخ / ملح الطعام) في كل قارورة. ھذا یعادل. ۰ .۲ ٪ من الحد الأقصى الموصى به من المدخول الغذائي الیومي من الصودیوم للشخص البالغ.</p><p dir="RTL">تریسوفا، ۱۰ ملغ / مل تحتوي على.٤.۳۷ ملغ كحد أقصى من الصودیوم (مكون رئیسي في الطبخ / ملح الطعام) في كل قارورة. وھذا یعادل ۹. ۱ &nbsp;٪ من الحد الأقصى الموصى بھ من المدخول الغذائي الیومي من الصودیوم للشخص البالغ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم ھذا الدواء دائمًا تمامًا كما أخبرك طبیبك أو الصیدلي. استشر طبیبك إذا لم تكن متأكداً.</p><p dir="RTL">یتم إعطاء تریسوفا كتسریب مستمر ، إما:</p><p dir="RTL">-تحت الجلد (تحت الجلد)عبر أنبوب صغیر (قنیة) توُضَع في بطنك أو فخذك.</p><p dir="RTL">أو،</p><p dir="RTL">-عن طریق الورید عن طریق أنبوب (قسطرة) یوجد عادة في رقبتك أو صدرك أو فخذك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في كلتا الحالتین ، یتم دفع تریسوفا عبر الأنبوب بواسطة مضخة محمولة.</p><p dir="RTL">قبل أن تغادر المستشفى أو العیادة، سیخبرك طبیبك بكیفیة تحضیر تریسوفا وبأي معدل یجب أن توصل المضخة تریبروستینیل الخاص بك. یجب أیضًا تزویدك بمعلومات حول كیفیة استخدام المضخة بشكل صحیح وماذا تفعل إذا توقفت عن العمل. یجب أن تخبرك المعلومات أیضًا بمن تتصل في حالة الطوارئ .</p><p dir="RTL">قد یؤدي شطف خط التسریب أثناء توصیلھ إلى جرعة زائدة عرضیة.</p><p dir="RTL">یتم تخفیف تریسوفا فقط عند تناولھ عن طریق الورید:</p><p dir="RTL">للتسریب في الورید فقط: یمكنك تخفیف محلول تریبروستینیل إما بالماء المعقم للحقن أو&nbsp; ۹. ۰٪ كلورید الصودیوم للحقن (على النحو المنصوص علیھ من قبل طبیبك) إذا كان یتم إعطاؤه كتسريب وريدي مستمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى</strong><strong> </strong><strong>البالغین</strong></p><p dir="RTL">تریسوفا متاح في محلول ٥ ملغ / مل أو ۱۰ ملغ / مل للتسریب. سیحدد طبیبك معدل التسریب والجرعة المناسبة لحالتك.</p><p dir="RTL"><strong>المرضى</strong><strong> </strong><strong>الذین</strong><strong> </strong><strong>لدیھم</strong><strong> </strong><strong>وزن</strong><strong> </strong><strong>زائ</strong><strong> </strong><strong>د</strong></p><p dir="RTL">إذا كنت تعاني من زیادة الوزن (تزن ۳۰ ٪ أو أكثر من وزن جسمك المثالي) ، فسیحدد طبیبك الجرعات الأولیة واللاحقة بناءً على وزنك المثالي. یرجى أیضًا الرجوع إلى القسم ۲ ، &quot;التحذیرات والاحتیاطات.&quot;</p><p dir="RTL"><strong>المرضى</strong><strong> </strong><strong>المسنین</strong></p><p dir="RTL">سیحدد طبیبك معدل التسریب والجرعة المناسبة لحالتك.</p><p dir="RTL"><strong>الاستخدام</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الأطفال</strong><strong> </strong><strong>والمراھقین</strong></p><p dir="RTL">لم یتم إثبات سلامة وفعالیة تریسوفا لدى الأطفال والمراھقین الذین تقل أعمارھم عن ۱۸ عامًا.</p><p dir="RTL">تعدیل الجرعة</p><p dir="RTL">یمكن خفض أو زیادة معدل التسریب على أساس فردي تحت إشراف طبي فقط.</p><p dir="RTL">الھدف من تعدیل معدل التسریب ھو إنشاء معدل صیانة فعال یحسن ارتفاع الضغط الرئوي الشریاني PAH مع تقلیل أي تأثیرات غیر مرغوب فیھ ا.</p><p dir="RTL">إذا زادت الأعراض أو إذا كنت بحاجة إلى راحة تامة، أو كنت ملزما في سریرك أو كرسیك، أو إذا كان أي نشاط بدني یسبب لك الشعور بعدم الراحة وتحدث الأعراض لك أثناء الراحة ، فلا تزید جرعتك دون استشارة طبیة. قد لا یكون ھذا الدواء كافیاً لعلاج مرضك وقد یتطلب الأمر علاجًا آخر.</p><p dir="RTL"><strong>كیف</strong><strong> </strong><strong>یمكن</strong><strong> </strong><strong>منع</strong><strong> </strong><strong>عدوى</strong><strong> </strong><strong>مجرى</strong><strong> </strong><strong>الدم</strong><strong> </strong><strong>أثناء</strong><strong> </strong><strong>العلاج</strong><strong> </strong><strong>باستخدام</strong><strong> </strong><strong>تریسوفا</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>طریق</strong><strong> </strong><strong>الورید؟</strong></p><p dir="RTL">كما ھو الحال مع أي علاج وریدي طویل الأمد، ھناك خطر الإصابة بعدوى مجرى الدم. سیقوم طبیبك بتدریبك على كیفیة تجنب ذلك.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>اخذت</strong><strong> </strong><strong>كمیة</strong><strong> </strong><strong>أكبر</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>ینبغي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>تریسوفا</strong></p><p dir="RTL">إذا تناولت جرعة زائدة عن طریق الخطأ من ھذا الدواء ، فقد تعاني من الغثیان والقيء والإسھال وانخفاض ضغط الدم (دوار ، والدوخة أو الإغماء) ، واحمرار الجلد و / أو الصداع.</p><p dir="RTL">إذا أصبحت أي من ھذه الآثار شدیدة ، فعلیك الاتصال بطبیبك أو المستشفى على الفور. قد یقلل طبیبك أو یوقف التسریب حتى تختفي الأعراض. سیتم بعد ذلك إعادة تقدیم محلول تریسوفا للتسریب بمستوى جرعة موصى بھ من قبل طبیبك.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسیت</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تأخ</strong><strong> </strong><strong>ذ</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>تستخدم</strong><strong> </strong><strong>تریسوفا</strong></p><p dir="RTL">اتصل بطبیبك أو المستشفى حالا</p><p dir="RTL">&nbsp;<strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>تریسوفا</strong></p><p dir="RTL">استخدم تریسوفا دائمًا وفقاً لتوجیھات الطبیب أو الأخصائي الطبي. لا تتوقف عن استخدام تریسوفا إلا إذا نصحك طبیبك بذلك.</p><p dir="RTL">قد یتسبب الانسحاب المفاجئ أو التخفیضات المفاجئة في جرعة تریبروستینیل في عودة ارتفاع ضغط الدم الشریاني الرئوي مع احتمال حدوث تدھور سریع وشدید في حالتك.</p><p dir="RTL">إذا كان لدیك أي أسئلة أخرى حول استخدام ھذا الدواء ، اسأل طبیبك أو الصیدلي أو الأخصائي الطبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثلھ مثل كافة الأدویة، قد یسُبب ھذا الدوَّاء آثارًا جانبیة، ومع ذلك، قد لاتحدث لدى الجمیع. كل الأعراض الجانبیة المذكورة في الأسفل قد تحدث بشدة مختلفة من طفیفة إلى حادةّ. في حال أدتّ أي من الأعراض المذكورة في الأسفل إلى تدھور صحتك بشكل حاد، علیك إبلاغ طبیبك فوراً.</p><p dir="RTL"><u>شائعة</u><u> </u><u>جدا</u><u> </u><u>( </u><u>قد</u><u> </u><u>تؤُثر</u><u> </u><u>على</u><u> </u><u>أكثر</u><u> </u><u>من</u><u> </u><u>شخص</u><u> </u><u>واحد</u><u> </u><u>من</u><u> </u><u>بین</u><u> </u><u>كل</u><u> </u><u>۱۰</u><u> </u><u>أشخاص</u><u>)</u><u> </u></p><p dir="RTL">&bull;اتساع الأوعیة الدمویة مع احمرار الجلد والشعور بالحرارة</p><p dir="RTL">&bull;ألم أو عدم ارتیاح حول موقع الحقن</p><p dir="RTL">&bull;تغیر لون الجلد أو ظھور كدمات حول مكان الحقن</p><p dir="RTL">&bull;صداع</p><p dir="RTL">&bull;طفح جلدي</p><p dir="RTL">&bull;غثیان</p><p dir="RTL">&bull;إسھال</p><p dir="RTL">&bull; ألم الفك</p><p dir="RTL"><u>شائعة</u><u>(</u><u>قد</u><u> </u><u>تؤُثر</u><u> </u><u>على</u><u> </u><u>ما</u><u> </u><u>یصل</u><u> </u><u>إلى</u><u> </u><u>شخص</u><u> </u><u>واحد</u><u> </u><u>من</u><u> </u><u>بین</u><u> </u><u>كل</u><u> </u><u>۱۰</u><u> </u><u>أشخاص</u><u>)</u></p><p dir="RTL">&bull;دوار</p><p dir="RTL">&bull;القيء</p><p dir="RTL">&bull;خفة الرأس أو الإغماء بسبب انخفاض ضغط الدم</p><p dir="RTL">&bull;حكة أو احمرار في الجلد</p><p dir="RTL">&bull;آلام العضلات وآلام المفاصل</p><p dir="RTL">&bull;تورم القدمین والكاحلین والساقین أو احتباس السوائل</p><p dir="RTL">&bull;نوبات نزیف مثل نزیف الأنف ، سعال مصحوب بالدم ، دم في البول ، نزیف من اللثة ، دم في البراز</p><p dir="RTL">&bull; ألم في الذراعین و / أو الساقین</p><p dir="RTL">غیر معروفة (لا یمكن تقدیر التكرار من البیانات المتاحة)</p><p dir="RTL">&bull;عدوى في موقع الحقن</p><p dir="RTL">&bull;خراج في موقع الحقن</p><p dir="RTL">&bull;انخفاض خلایا تخثر الدم (الصفائح الدمویة) في الدم(قلة الصفیحات الدمویة)</p><p dir="RTL">&bull;نزیف في موقع الحقن</p><p dir="RTL">&bull;آلام العظام</p><p dir="RTL">&bull;طفح جلدي مع تغیر في اللون أو نتوءات بارزة</p><p dir="RTL">&bull;عدوى الأنسجة تحت الجلد (التھاب النسیج الخلوي)</p><p dir="RTL">&bull;الضخ المفرط للدم من القلب مما یؤدي إلى ضیق التنفس ، والتعب ، وتورم الساقین والبطن بسبب تراكم السوائل ، والسعال المستمر</p><p dir="RTL">الأعراض الجانبیة الإضافیة المرتبطة بالطریق الوریدي للإعطاء (لا یمكن تقدیر مدى حدوثھا من البیانات المتاحة)</p><p dir="RTL">&bull;التھاب الورید (التھاب الورید الخثاري)</p><p dir="RTL">&bull;عدوى بكتیریة في مجرى الدم (تجرثم الدم) * (راجع القسم 3)</p><p dir="RTL">&bull;تسمم الدم (عدوى بكتیریة شدیدة في الدم)</p><p dir="RTL">*تم الإبلاغ عن حالات تھدد الحیاة أو ممیتة من العدوى البكتیریة في مجرى الدم</p><p dir="RTL"><strong>الإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>الأعراض</strong><strong> </strong><strong>الجانبیة</strong></p><p dir="RTL">إذا ظھرت لدیك أیة آعراض جانبیة، فتحدث إلى طبیبك أو الصیدلي الخاص بك. یشمل ذلك أیة أعراض جانبیة مُحتمَلة غیر</p><p dir="RTL">مُدرجة في ھذه النشَّرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفَظ في درجة حرارة أقل من 30 درجة مئوية</p><p dir="RTL">یحُفظ ھذا الدوَّاء بعیداً عن رؤیة ومُتناوَل الأطفال.</p><p dir="RTL">لا تستعمل ھذا الدوَّاء بعد تاریخ انتھاء الصلاحیة المدون على العبوة الكرتونیة وعلى القارورة بعد كلمة &quot; EXP &quot;یشُیر تاریخ.</p><p dir="RTL">انتھاء الصَّلاحیة إلى الیوم الأخیر من ذلك الشھر.</p><p dir="RTL">لا تستخدم ھذا الدواء إذا لاحظت أي تلف في القارورة أو تغیر اللون أو أي علامات أخرى للتدھور.</p><p dir="RTL">بعد الفتح لأول مرة ، یجب استخدام قارورة تریسوفا أو التخلص منھا في غضون ۳۰ یومًا ویجب تخزینھا في درجة حرارة أقل من ۳۰ درجة مئویة.</p><p dir="RTL">أثناء التسریب المستمر تحت الجلد ، یجب استخدام خزان واحد (حقنة) غیر مخففة من تریسوفا في غضون ۱٤ یومًا.</p><p dir="RTL">أثناء التسریب المستمر في الورید ، یجب استخدام خزان واحد (حقنة) من تریسوفا المخفف في غضون ۲٤ ساعة.</p><p dir="RTL">یجب التخلص من أي محلول مخفف متبقي.</p><p dir="RTL">لا تتخلص من الأدویة عن طریق إلقائھا في میاه الصَّرف أو مع المخلفات المنزلیة. استشر الصیدلي الخاص بك عن كيفية التخَّلص من الأدویة التي لم تعَدُ تستخدمھا. ستسُاعد ھذه الإجراءات في الحفاظ على البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتویات</strong><strong> </strong><strong>تریسوفا</strong></p><p dir="RTL">-المادة الفعالة ھي تریبروستینیل</p><p dir="RTL">تحتوي محلول ۱ مل للتسریب على ٥ ملغ، أو ۱۰ ملغ(على شكل تریبروستینیل الصودیوم) ، على التوالي.</p><p dir="RTL">- المكونات الأخرى ھي:</p><p dir="RTL">میتاكریسول وسیترات الصودیوم (ثنائي ھیدرات) وكلورید الصودیوم وحمض الھیدروكلوریك وھیدروكسید الصودیوم والماء</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تریسوفا عبارة عن محلول شفاف عدیم اللون إلى أصفر قلیلا خالي من الجزیئات المرئیة ، وھو متوفر في قارورة زجاجیة شفافة محكمة الإغلاق بسدادة مطاطیة وغطاء ألومنیوم مرمز بالألوان:</p><p dir="RTL">&bull;محلول تریسوفا ٥ ملغ/ مل للتسریب ذو غطاء أخضر من الألومنیوم.</p><p dir="RTL">&bull;یحتوي محلول تریسوفا ۱۰ ملغ/ مل للتسریب على غطاء من الألومنیوم بلون أرجواني.</p><p dir="RTL">تحتوي كل كرتونة على قارورة واحدة سعة ۱۰ مل من محلول التسریب</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك</strong><strong> </strong><strong>حق</strong><strong> </strong><strong>التسَّویق</strong></p><p dir="RTL">إي أو بي أورفان فارماسوتیكلس ج م ب اتش</p><p dir="RTL">لیوبولد أنغار بلاتز ۲</p><p dir="RTL">&nbsp;</p><p dir="RTL">۱۱۹۰ فیینا، النمسا</p><p dir="RTL"><strong>المُصنِّع</strong></p><p dir="RTL">لایوكونتراكت جي ام بي ات ش</p><p dir="RTL">بلفرفیزا ۱، إلزنبرج، ألمانیا</p><p dir="RTL">تمت آخر مراجعة لھذه النشَّرة في ینایر 2023 ( الرقم المرجعي: (SA-MAA- 01</p><p dir="RTL">للإبلاغ عن الأعراض الجانبیة التي قد تحدث، یرجى التواصل عبر العناوین التالیة :</p><p dir="RTL"><strong>المملكة</strong><strong> </strong><strong>العربیة</strong><strong> </strong><strong>السعودیة</strong><strong>:</strong></p><p dir="RTL">المركز الوطني للتیقظ والسلامة الدوائیة : (NPC)</p><p dir="RTL">مركز اتصال الھیئة العامة للغذاء والدواء : ۱۹۹۹۹</p><p dir="RTL">البرید الإلكترونني: &nbsp;npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني https://ade.sfda.gov.sa :</p><p dir="RTL"><strong>الإمارات</strong><strong> </strong><strong>العربیة</strong><strong> </strong><strong>المتحدة</strong><strong>:</strong></p><p dir="RTL">قسم التیقظ الدوائي والأجھزة الطبیة</p><p dir="RTL">صندوق برید: ۱۸٥۳ ، ھاتف: ۸۰۰۱۱۱۱۱</p><p dir="RTL">البرید الإلكتروني pv@mohap.gov.ae :</p><p dir="RTL">قسم الدواء</p><p dir="RTL">وزارة الصحة ووقایة المجتمع</p><p dir="RTL">دبي، الامارات العربیة المتحد ة</p><p dir="RTL"><strong>سلطنة</strong><strong> </strong><strong>عُمان</strong></p><p dir="RTL">قسم التیقظ الدوائي والمعلومات الدوائی ة</p><p dir="RTL">المدیریة العامة للشؤون الصیدلانیة والرقابة الدوائی ة</p><p dir="RTL">وزارة الصحة ، سلطنة عمان</p><p dir="RTL">۰۰۹٦۸۲۲۳٥۷٦۸۷/ ھاتف: ۰۰۹٦۸۲۲۳٥۷٦۸٦</p><p dir="RTL">الفاكس: ۰۰۹٦۸۲۲۳٥۸٤۸۹</p><p dir="RTL">البرید الإلكتروني pharma-vigil@moh.gov.om :</p><p dir="RTL">الموقع www.moh.gov.om :</p><p dir="RTL">عبر إبلاغك عن الأعراض الجانبیة، یمكنك المساعدة في تزوید معلومات أكثر عن سلامة الدوا ء</p><p dir="RTL"><strong>ھذا</strong><strong> </strong><strong>مُنتجَ</strong><strong> </strong><strong>دوائي</strong></p><p dir="RTL">&ndash; الدوَّاء مستحضر یؤُثر على صحتك و استھلاكك خلاف اً للتعّلیمات یعرضك للخطر.</p><p dir="RTL">- اتبع بدقة وصفة الطبیب وطریقة الاستعمال المنصوص علیھا وتعلیمات الصیدلي الذي صرفھا لك.</p><p dir="RTL">- الطبیب والصیدلي ھما الخبیران في الدواء وفي نفعھ وضرره.</p><p dir="RTL">- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">- لا تكرر صرف الدواء بدون استشارة الطبیب المختص.</p><p dir="RTL">لا تترك الأدویة في مُتناوَل الأطفال.</p><p dir="RTL">مجلس وزراء الصحة العرب واتحاد الصیادلة العرب</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trisuva, 5 mg/ml solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains 5 mg treprostinil, as treprostinil sodium.
Each 10 ml vial of solution contains 50 mg treprostinil as treprostinil sodium.
Excipients with known effect:
sodium: maximum 39.1 mg per vial
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion for subcutaneous or intravenous administration:
Clear, colourless to slightly yellow solution
pH value between 6.0 and 7.2.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of idiopathic or heritable pulmonary arterial hypertension (PAH) to improve exercise tolerance and symptoms of the disease in patients classified as New York Heart Association (NYHA) functional class III.</p><p>Trisuva is used in adults (18 years and older).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Trisuva is administered by subcutaneous or intravenous continuous infusion. Due to the risks associated with chronic indwelling central venous catheters, including serious blood stream infections, subcutaneous infusion (undiluted) is the preferred mode of administration and continuous intravenous infusion should be reserved for patients stabilised with treprostinil subcutaneous infusion and who become intolerant of the subcutaneous route, and in whom these risks are considered acceptable.</p><p>The treatment should be initiated and monitored only by clinicians experienced in the treatment of pulmonary hypertension.</p><p>&nbsp;</p><p><u>Dosage (posology)</u></p><p>&nbsp;</p><p><strong><em>In adults</em></strong></p><p><u>Treatment initiation for patients new to prostacyclin therapy</u></p><p>&nbsp;</p><p>Treatment should be initiated under close medical supervision in a medical setting able to provide intensive care.</p><p>&nbsp;</p><p>The recommended initial infusion rate is 1.25 ng/kg/min. If this initial dose is poorly tolerated, the infusion rate should be reduced to 0.625 ng/kg/min.</p><p>&nbsp;</p><p><u>Dose adjustments</u></p><p>The infusion rate should be increased under medical supervision in increments of 1.25 ng/kg/min per week for the first four weeks of treatment and then 2.5 ng/kg/min per week.</p><p>&nbsp;</p><p>The dose should be adjusted on an individual basis and under medical supervision in order to achieve a maintenance dose at which symptoms improve and which is tolerated by patients with pulmonary arterial hypertension symptoms.</p><p>&nbsp;</p><p>Efficacy in the main 12-week trials was only maintained if the dose was increased on an average 3-4 times per month. The goal of chronic dosage adjustments is to establish a dose at which PAH symptoms are improved, whilst minimizing the excessive pharmacological effects of treprostinil.</p><p>&nbsp;</p><p>Adverse effects, such as flushing, headache, hypotension, nausea, vomiting and diarrhoea, are generally dependent on the dose of treprostinil administered. They may decrease as treatment continues, but should they persist or become intolerable to the patient, the infusion rate may be reduced to diminish their intensity.</p><p>&nbsp;</p><p>During follow-up phases of clinical trials the mean doses reached after 12 months were 26 ng/kg/min, after 24 months they were 36 ng/kg/min, and after 48 months they were 2 ng/kg/min.</p><p>For patients with obesity (weighing &gt; 30% more than ideal body weight) initial dose and following dose increments should be based on ideal body weight.</p><p>&nbsp;</p><p>Abrupt withdrawal or sudden marked reductions in the dose of treprostinil may cause a rebound in pulmonary arterial hypertension. It is therefore recommended that interruption of treprostinil therapy is avoided and that the infusion is re-started as soon as possible after an abrupt accidental dose reduction or interruption. The optimal strategy for reintroducing treprostinil infusion needs to be determined on a case by case basis by medically qualified personnel. In most cases, after an interruption of a few hours, restarting of treprostinil infusion can be done using the same dose rate; interruptions for longer periods may require the dose of treprostinil to be re-titrated.</p><p>&nbsp;</p><p><strong><em>In elderly patients</em></strong></p><p>Clinical studies of treprostinil did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In a population pharmacokinetic (PK) analysis, plasma clearance of treprostinil was reduced by 20%. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p><p>&nbsp;</p><p><strong><em>Paediatric population</em></strong></p><p>There are few data in patients less than 18 years of age. Available clinical studies do not establish whether the efficacy and safety of the recommended posology scheme for adults can be extrapolated to children and adolescents.</p><p>&nbsp;</p><p><strong><em>At-risk populations</em></strong></p><p><em>Hepatic impairment</em>&nbsp;Plasma treprostinil exposure (area under the plasma concentration-time curve; AUC) increases by 260% to 510% in mild to moderate hepatic impairment, Child-Pugh classes A and B, respectively. Plasma clearance of treprostinil was reduced by up to 80% in subjects presenting with mild to moderate hepatic impairment. Caution is therefore advised when treating patients with hepatic impairment because of the risk of an increase in systemic exposure which may reduce tolerability and lead to an increase in dosedependent adverse effects.</p><p>&nbsp;</p><p>&nbsp;</p><p>The initial dose of treprostinil should be decreased to 0.625 ng/kg/min and incremental dose increases should be made cautiously.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>As no clinical studies have been carried out in patients with renal impairment, the treatment recommendations are not established for patients with renal impairment. As treprostinil and its metabolites are excreted mainly through the urinary route, caution is recommended when treating patients with renal impairment in order to prevent deleterious consequences related to the possible increase of systemic exposure.</p><p>&nbsp;</p><p><strong><em>Method of transition to intravenous epoprostenol treatment</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>When transition to intravenous epoprostenol is required, the transition phase should take place under strict medical supervision. It may be useful for guidance purposes to note the following suggested treatment transition scheme. Treprostinil infusions should first be decreased slowly by 2.5 ng/kg/min.</p><p>After at least 1 hour at the new treprostinil dose, epoprostenol treatment can be initiated at a maximum dose of 2 ng/kg/min. The treprostinil dose should then be decreased at subsequent intervals of at least 2 hours, and at the same time the epoprostenol dose is gradually increased after maintaining the initial dose for at least one hour.</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>For subcutaneous or intravenous administration</p><p>&nbsp;</p><p><strong>Administration by continuous subcutaneous infusion</strong></p><p><strong>&nbsp;</strong></p><p>Trisuva is administered by continuous subcutaneous infusion via a subcutaneous catheter using an ambulatory infusion pump.</p><p>&nbsp;</p><p>In order to avoid potential interruptions in drug delivery, the patient must have access to a backup infusion pump and subcutaneous infusion sets in the event that the administration equipment should suffer an accidental malfunction.</p><p>&nbsp;</p><p>The ambulatory infusion pump used to administer undiluted Trisuva subcutaneously should be:</p><p>&nbsp;</p><p>1) small and lightweight,</p><p>2) capable of adjusting infusion rates in increments of approximately 0.002 ml/h,</p><p>3) fitted with occlusion, low battery, programming error and malfunction alarms,</p><p>4) accurate to within +/- 6% of the programmed delivery rate</p><p>5) positive pressure driven (continuous or pulsated).</p><p>&nbsp;</p><p>The reservoir must be made of polyvinyl chloride, polypropylene or glass.</p><p>&nbsp;</p><p>Patients must be thoroughly trained in the use and programming of the pump, and the connection and care of the infusion set.</p><p>&nbsp;</p><p>Flushing the infusion line whilst connected to the patient may lead to accidental overdose.</p><p>&nbsp;</p><p>Infusion rates &nabla; (ml/h) are calculated using the following formula:</p><p>&nabla; (ml/h) = D (ng/kg/min) x W (kg) x [0.00006/treprostinil concentration (mg/ml)]</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>D = prescribed dose expressed in ng/kg/min</p><p>W = body weight of the patient expressed in kg</p><p>&nbsp;</p><p>Trisuva is available at concentrations of 1mg/ml, 2.5 mg/ml, 5 mg/ml and 10 mg/ml.</p><p>&nbsp;</p><p>For subcutaneous infusion, Trisuva is <strong>delivered without further dilution </strong>at a calculated Subcutaneous Infusion Rate (ml/h) based on a patient&rsquo;s dose (ng/kg/min), Weight (kg), and the Vial Strength (mg/ml) of Trisuva being used (see table 1). During use, a single reservoir (syringe) of undiluted trepostinil can be administered for up to 14 days at 37&deg;C.</p><p>The Subcutaneous Infusion rate is calculated using the following formula:</p><p>&nbsp;</p><p><strong>Subcutaneous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose </strong>(ng/kg/min)&nbsp; <strong>x&nbsp; Weight </strong>(kg)&nbsp; <strong>x&nbsp; 0.00006*</strong></p><p><strong>Infusion Rate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; = &nbsp;&nbsp;------------------------------------------------------------------</strong></p><p>(ml/h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Trisuva Vial Strength </strong>(mg/ml)</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><em>*Conversion factor of 0.00006 = 60 min </em>&agrave; <em>hour x 0.000001 mg</em> &agrave;<em>ng</em></p><p><em>&nbsp;</em></p><p>Example calculations for <strong><em>Subcutaneous Infusion </em></strong>are as follows:</p><p>&nbsp;</p><p><strong><em>Example 1:</em></strong></p><p>For a 60 kg person at the recommended initial dose of 1.25 ng/kg/min using the 1 mg/ml Trisuva Vial Strength, the infusion rate would be calculated as follows:</p><p>&nbsp;</p><p><strong>Subcutaneous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.25 </strong>ng/kg/min <strong>x 60 </strong>kg <strong>x 0.00006</strong></p><p><strong>Infusion Rate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; =&nbsp;&nbsp;&nbsp; --------------------------------------------------------&nbsp;&nbsp;&nbsp; =&nbsp;&nbsp;&nbsp; 0.005 </strong>ml/h</p><p>(ml/h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>1 </strong>mg/ml</p><p><strong>&nbsp;</strong></p><p><u>&nbsp;</u></p><p><strong><em>Example 2:</em></strong></p><p>For a 65 kg person at a dose of 40 ng/kg/min using the 5 mg/ml Trisuva Vial Strength, the infusion rate would be calculated as follows:</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Subcutaneous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40 </strong>ng/kg/min&nbsp; <strong>x&nbsp; 65 </strong>kg&nbsp; <strong>x&nbsp; 0.00006 </strong></p><p><strong>Infusion Rate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; =&nbsp;&nbsp;&nbsp; --------------------------------------------------------&nbsp;&nbsp;&nbsp; =&nbsp;&nbsp;&nbsp; 0.031 </strong>ml/h</p><p>(ml/h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>5 </strong>mg/ml</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 1 provides guidance for Trisuva 5 mg/ml <strong>subcutaneous </strong>infusion delivery rates for patients of different body weights corresponding to doses of up to 80 ng/kg/min.</p><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infusion rate setting of subcutaneous pump (ml/h) for Trisuva</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at a treprostinil concentration of 5 mg/ml</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Weight (kg)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Dose (ng/kg/min)</strong></p></td><td style="vertical-align:top"><p><strong>35</strong></p></td><td style="vertical-align:top"><p><strong>40</strong></p></td><td style="vertical-align:top"><p><strong>45</strong></p></td><td style="vertical-align:top"><p><strong>50</strong></p></td><td style="vertical-align:top"><p><strong>55</strong></p></td><td style="vertical-align:top"><p><strong>60</strong></p></td><td style="vertical-align:top"><p><strong>65</strong></p></td><td style="vertical-align:top"><p><strong>70</strong></p></td><td style="vertical-align:top"><p><strong>75</strong></p></td><td style="vertical-align:top"><p><strong>80</strong></p></td><td style="vertical-align:top"><p><strong>85</strong></p></td><td style="vertical-align:top"><p><strong>90</strong></p></td><td style="vertical-align:top"><p><strong>95</strong></p></td><td style="vertical-align:top"><p><strong>100</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>10</strong></p></td><td style="vertical-align:top"><p>0.004</p></td><td style="vertical-align:top"><p>0.005</p></td><td style="vertical-align:top"><p>0.005</p></td><td style="vertical-align:top"><p>0.006</p></td><td style="vertical-align:top"><p>0.007</p></td><td style="vertical-align:top"><p>0.007</p></td><td style="vertical-align:top"><p>0.008</p></td><td style="vertical-align:top"><p>0.008</p></td><td style="vertical-align:top"><p>0.009</p></td><td style="vertical-align:top"><p>0.010</p></td><td style="vertical-align:top"><p>0.010</p></td><td style="vertical-align:top"><p>0.011</p></td><td style="vertical-align:top"><p>0.011</p></td><td style="vertical-align:top"><p>0.012</p></td></tr><tr><td style="vertical-align:top"><p><strong>12.5</strong></p></td><td style="vertical-align:top"><p>0.005</p></td><td style="vertical-align:top"><p>0.006</p></td><td style="vertical-align:top"><p>0.007</p></td><td style="vertical-align:top"><p>0.008</p></td><td style="vertical-align:top"><p>0.008</p></td><td style="vertical-align:top"><p>0.009</p></td><td style="vertical-align:top"><p>0.010</p></td><td style="vertical-align:top"><p>0.011</p></td><td style="vertical-align:top"><p>0.011</p></td><td style="vertical-align:top"><p>0.012</p></td><td style="vertical-align:top"><p>0.013</p></td><td style="vertical-align:top"><p>0.014</p></td><td style="vertical-align:top"><p>0.014</p></td><td style="vertical-align:top"><p>0.015</p></td></tr><tr><td style="vertical-align:top"><p><strong>15</strong></p></td><td style="vertical-align:top"><p>0.006</p></td><td style="vertical-align:top"><p>0.007</p></td><td style="vertical-align:top"><p>0.008</p></td><td style="vertical-align:top"><p>0.009</p></td><td style="vertical-align:top"><p>0.010</p></td><td style="vertical-align:top"><p>0.011</p></td><td style="vertical-align:top"><p>0.012</p></td><td style="vertical-align:top"><p>0.013</p></td><td style="vertical-align:top"><p>0.014</p></td><td style="vertical-align:top"><p>0.014</p></td><td style="vertical-align:top"><p>0.015</p></td><td style="vertical-align:top"><p>0.016</p></td><td style="vertical-align:top"><p>0.017</p></td><td style="vertical-align:top"><p>0.018</p></td></tr><tr><td style="vertical-align:top"><p><strong>17.5</strong></p></td><td style="vertical-align:top"><p>0.007</p></td><td style="vertical-align:top"><p>0.008</p></td><td style="vertical-align:top"><p>0.009</p></td><td style="vertical-align:top"><p>0.011</p></td><td style="vertical-align:top"><p>0.012</p></td><td style="vertical-align:top"><p>0.013</p></td><td style="vertical-align:top"><p>0.014</p></td><td style="vertical-align:top"><p>0.015</p></td><td style="vertical-align:top"><p>0.016</p></td><td style="vertical-align:top"><p>0.017</p></td><td style="vertical-align:top"><p>0.018</p></td><td style="vertical-align:top"><p>0.019</p></td><td style="vertical-align:top"><p>0.020</p></td><td style="vertical-align:top"><p>0.021</p></td></tr><tr><td style="vertical-align:top"><p><strong>20</strong></p></td><td style="vertical-align:top"><p>0.008</p></td><td style="vertical-align:top"><p>0.010</p></td><td style="vertical-align:top"><p>0.011</p></td><td style="vertical-align:top"><p>0.012</p></td><td style="vertical-align:top"><p>0.013</p></td><td style="vertical-align:top"><p>0.014</p></td><td style="vertical-align:top"><p>0.016</p></td><td style="vertical-align:top"><p>0.017</p></td><td style="vertical-align:top"><p>0.018</p></td><td style="vertical-align:top"><p>0.019</p></td><td style="vertical-align:top"><p>0.020</p></td><td style="vertical-align:top"><p>0.022</p></td><td style="vertical-align:top"><p>0.023</p></td><td style="vertical-align:top"><p>0.024</p></td></tr><tr><td style="vertical-align:top"><p><strong>22.5</strong></p></td><td style="vertical-align:top"><p>0.009</p></td><td style="vertical-align:top"><p>0.011</p></td><td style="vertical-align:top"><p>0.012</p></td><td style="vertical-align:top"><p>0.014</p></td><td style="vertical-align:top"><p>0.015</p></td><td style="vertical-align:top"><p>0.016</p></td><td style="vertical-align:top"><p>0.018</p></td><td style="vertical-align:top"><p>0.019</p></td><td style="vertical-align:top"><p>0.020</p></td><td style="vertical-align:top"><p>0.022</p></td><td style="vertical-align:top"><p>0.023</p></td><td style="vertical-align:top"><p>0.024</p></td><td style="vertical-align:top"><p>0.026</p></td><td style="vertical-align:top"><p>0.027</p></td></tr><tr><td style="vertical-align:top"><p><strong>25</strong></p></td><td style="vertical-align:top"><p>0.011</p></td><td style="vertical-align:top"><p>0.012</p></td><td style="vertical-align:top"><p>0.014</p></td><td style="vertical-align:top"><p>0.015</p></td><td style="vertical-align:top"><p>0.017</p></td><td style="vertical-align:top"><p>0.018</p></td><td style="vertical-align:top"><p>0.020</p></td><td style="vertical-align:top"><p>0.021</p></td><td style="vertical-align:top"><p>0.023</p></td><td style="vertical-align:top"><p>0.024</p></td><td style="vertical-align:top"><p>0.026</p></td><td style="vertical-align:top"><p>0.027</p></td><td style="vertical-align:top"><p>0.029</p></td><td style="vertical-align:top"><p>0.030</p></td></tr><tr><td style="vertical-align:top"><p><strong>27.5</strong></p></td><td style="vertical-align:top"><p>0.012</p></td><td style="vertical-align:top"><p>0.013</p></td><td style="vertical-align:top"><p>0.015</p></td><td style="vertical-align:top"><p>0.017</p></td><td style="vertical-align:top"><p>0.018</p></td><td style="vertical-align:top"><p>0.020</p></td><td style="vertical-align:top"><p>0.021</p></td><td style="vertical-align:top"><p>0.023</p></td><td style="vertical-align:top"><p>0.025</p></td><td style="vertical-align:top"><p>0.026</p></td><td style="vertical-align:top"><p>0.028</p></td><td style="vertical-align:top"><p>0.030</p></td><td style="vertical-align:top"><p>0.031</p></td><td style="vertical-align:top"><p>0.033</p></td></tr><tr><td style="vertical-align:top"><p><strong>30</strong></p></td><td style="vertical-align:top"><p>0.013</p></td><td style="vertical-align:top"><p>0.014</p></td><td style="vertical-align:top"><p>0.016</p></td><td style="vertical-align:top"><p>0.018</p></td><td style="vertical-align:top"><p>0.020</p></td><td style="vertical-align:top"><p>0.022</p></td><td style="vertical-align:top"><p>0.023</p></td><td style="vertical-align:top"><p>0.025</p></td><td style="vertical-align:top"><p>0.027</p></td><td style="vertical-align:top"><p>0.029</p></td><td style="vertical-align:top"><p>0.031</p></td><td style="vertical-align:top"><p>0.032</p></td><td style="vertical-align:top"><p>0.034</p></td><td style="vertical-align:top"><p>0.036</p></td></tr><tr><td style="vertical-align:top"><p><strong>32.5</strong></p></td><td style="vertical-align:top"><p>0.014</p></td><td style="vertical-align:top"><p>0.016</p></td><td style="vertical-align:top"><p>0.018</p></td><td style="vertical-align:top"><p>0.020</p></td><td style="vertical-align:top"><p>0.021</p></td><td style="vertical-align:top"><p>0.023</p></td><td style="vertical-align:top"><p>0.025</p></td><td style="vertical-align:top"><p>0.027</p></td><td style="vertical-align:top"><p>0.029</p></td><td style="vertical-align:top"><p>0.031</p></td><td style="vertical-align:top"><p>0.033</p></td><td style="vertical-align:top"><p>0.035</p></td><td style="vertical-align:top"><p>0.037</p></td><td style="vertical-align:top"><p>0.039</p></td></tr><tr><td style="vertical-align:top"><p><strong>35</strong></p></td><td style="vertical-align:top"><p>0.015</p></td><td style="vertical-align:top"><p>0.017</p></td><td style="vertical-align:top"><p>0.019</p></td><td style="vertical-align:top"><p>0.021</p></td><td style="vertical-align:top"><p>0.023</p></td><td style="vertical-align:top"><p>0.025</p></td><td style="vertical-align:top"><p>0.027</p></td><td style="vertical-align:top"><p>0.029</p></td><td style="vertical-align:top"><p>0.032</p></td><td style="vertical-align:top"><p>0.034</p></td><td style="vertical-align:top"><p>0.036</p></td><td style="vertical-align:top"><p>0.038</p></td><td style="vertical-align:top"><p>0.040</p></td><td style="vertical-align:top"><p>0.042</p></td></tr><tr><td style="vertical-align:top"><p><strong>37.5</strong></p></td><td style="vertical-align:top"><p>0.016</p></td><td style="vertical-align:top"><p>0.018</p></td><td style="vertical-align:top"><p>0.020</p></td><td style="vertical-align:top"><p>0.023</p></td><td style="vertical-align:top"><p>0.025</p></td><td style="vertical-align:top"><p>0.027</p></td><td style="vertical-align:top"><p>0.029</p></td><td style="vertical-align:top"><p>0.032</p></td><td style="vertical-align:top"><p>0.034</p></td><td style="vertical-align:top"><p>0.036</p></td><td style="vertical-align:top"><p>0.038</p></td><td style="vertical-align:top"><p>0.041</p></td><td style="vertical-align:top"><p>0.043</p></td><td style="vertical-align:top"><p>0.045</p></td></tr><tr><td style="vertical-align:top"><p><strong>40</strong></p></td><td style="vertical-align:top"><p>0.017</p></td><td style="vertical-align:top"><p>0.019</p></td><td style="vertical-align:top"><p>0.022</p></td><td style="vertical-align:top"><p>0.024</p></td><td style="vertical-align:top"><p>0.026</p></td><td style="vertical-align:top"><p>0.029</p></td><td style="vertical-align:top"><p>0.031</p></td><td style="vertical-align:top"><p>0.034</p></td><td style="vertical-align:top"><p>0.036</p></td><td style="vertical-align:top"><p>0.038</p></td><td style="vertical-align:top"><p>0.041</p></td><td style="vertical-align:top"><p>0.043</p></td><td style="vertical-align:top"><p>0.046</p></td><td style="vertical-align:top"><p>0.048</p></td></tr><tr><td style="vertical-align:top"><p><strong>42.5</strong></p></td><td style="vertical-align:top"><p>0.018</p></td><td style="vertical-align:top"><p>0.020</p></td><td style="vertical-align:top"><p>0.023</p></td><td style="vertical-align:top"><p>0.026</p></td><td style="vertical-align:top"><p>0.028</p></td><td style="vertical-align:top"><p>0.031</p></td><td style="vertical-align:top"><p>0.033</p></td><td style="vertical-align:top"><p>0.036</p></td><td style="vertical-align:top"><p>0.038</p></td><td style="vertical-align:top"><p>0.041</p></td><td style="vertical-align:top"><p>0.043</p></td><td style="vertical-align:top"><p>0.046</p></td><td style="vertical-align:top"><p>0.048</p></td><td style="vertical-align:top"><p>0.051</p></td></tr><tr><td style="vertical-align:top"><p><strong>45</strong></p></td><td style="vertical-align:top"><p>0.019</p></td><td style="vertical-align:top"><p>0.022</p></td><td style="vertical-align:top"><p>0.024</p></td><td style="vertical-align:top"><p>0.027</p></td><td style="vertical-align:top"><p>0.030</p></td><td style="vertical-align:top"><p>0.032</p></td><td style="vertical-align:top"><p>0.035</p></td><td style="vertical-align:top"><p>0.038</p></td><td style="vertical-align:top"><p>0.041</p></td><td style="vertical-align:top"><p>0.043</p></td><td style="vertical-align:top"><p>0.046</p></td><td style="vertical-align:top"><p>0.049</p></td><td style="vertical-align:top"><p>0.051</p></td><td style="vertical-align:top"><p>0.054</p></td></tr><tr><td style="vertical-align:top"><p><strong>47.5</strong></p></td><td style="vertical-align:top"><p>0.020</p></td><td style="vertical-align:top"><p>0.023</p></td><td style="vertical-align:top"><p>0.026</p></td><td style="vertical-align:top"><p><strong>0.029</strong></p></td><td style="vertical-align:top"><p>0.031</p></td><td style="vertical-align:top"><p>0.034</p></td><td style="vertical-align:top"><p>0.037</p></td><td style="vertical-align:top"><p>0.040</p></td><td style="vertical-align:top"><p>0.043</p></td><td style="vertical-align:top"><p>0.046</p></td><td style="vertical-align:top"><p>0.048</p></td><td style="vertical-align:top"><p>0.051</p></td><td style="vertical-align:top"><p>0.054</p></td><td style="vertical-align:top"><p>0.057</p></td></tr><tr><td style="vertical-align:top"><p><strong>50</strong></p></td><td style="vertical-align:top"><p>0.021</p></td><td style="vertical-align:top"><p>0.024</p></td><td style="vertical-align:top"><p>0.027</p></td><td style="vertical-align:top"><p>0.030</p></td><td style="vertical-align:top"><p>0.033</p></td><td style="vertical-align:top"><p>0.036</p></td><td style="vertical-align:top"><p>0.039</p></td><td style="vertical-align:top"><p>0.042</p></td><td style="vertical-align:top"><p>0.045</p></td><td style="vertical-align:top"><p>0.048</p></td><td style="vertical-align:top"><p>0.051</p></td><td style="vertical-align:top"><p>0.054</p></td><td style="vertical-align:top"><p>0.057</p></td><td style="vertical-align:top"><p>0.060</p></td></tr><tr><td style="vertical-align:top"><p><strong>55</strong></p></td><td style="vertical-align:top"><p>0.023</p></td><td style="vertical-align:top"><p>0.026</p></td><td style="vertical-align:top"><p>0.030</p></td><td style="vertical-align:top"><p>0.033</p></td><td style="vertical-align:top"><p>0.036</p></td><td style="vertical-align:top"><p>0.040</p></td><td style="vertical-align:top"><p>0.043</p></td><td style="vertical-align:top"><p>0.046</p></td><td style="vertical-align:top"><p>0.050</p></td><td style="vertical-align:top"><p>0.053</p></td><td style="vertical-align:top"><p>0.056</p></td><td style="vertical-align:top"><p>0.059</p></td><td style="vertical-align:top"><p>0.063</p></td><td style="vertical-align:top"><p>0.066</p></td></tr><tr><td style="vertical-align:top"><p><strong>60</strong></p></td><td style="vertical-align:top"><p>0.025</p></td><td style="vertical-align:top"><p>0.029</p></td><td style="vertical-align:top"><p>0.032</p></td><td style="vertical-align:top"><p>0.036</p></td><td style="vertical-align:top"><p>0.040</p></td><td style="vertical-align:top"><p>0.043</p></td><td style="vertical-align:top"><p>0.047</p></td><td style="vertical-align:top"><p>0.050</p></td><td style="vertical-align:top"><p>0.054</p></td><td style="vertical-align:top"><p>0.058</p></td><td style="vertical-align:top"><p>0.061</p></td><td style="vertical-align:top"><p>0.065</p></td><td style="vertical-align:top"><p>0.068</p></td><td style="vertical-align:top"><p>0.072</p></td></tr><tr><td style="vertical-align:top"><p><strong>65</strong></p></td><td style="vertical-align:top"><p>0.027</p></td><td style="vertical-align:top"><p>0.031</p></td><td style="vertical-align:top"><p>0.035</p></td><td style="vertical-align:top"><p>0.039</p></td><td style="vertical-align:top"><p>0.043</p></td><td style="vertical-align:top"><p>0.047</p></td><td style="vertical-align:top"><p>0.051</p></td><td style="vertical-align:top"><p>0.055</p></td><td style="vertical-align:top"><p>0.059</p></td><td style="vertical-align:top"><p>0.062</p></td><td style="vertical-align:top"><p>0.066</p></td><td style="vertical-align:top"><p>0.070</p></td><td style="vertical-align:top"><p>0.074</p></td><td style="vertical-align:top"><p>0.078</p></td></tr><tr><td style="vertical-align:top"><p><strong>70</strong></p></td><td style="vertical-align:top"><p>0.029</p></td><td style="vertical-align:top"><p>0.034</p></td><td style="vertical-align:top"><p>0.038</p></td><td style="vertical-align:top"><p>0.042</p></td><td style="vertical-align:top"><p>0.046</p></td><td style="vertical-align:top"><p>0.050</p></td><td style="vertical-align:top"><p>0.055</p></td><td style="vertical-align:top"><p>0.059</p></td><td style="vertical-align:top"><p>0.063</p></td><td style="vertical-align:top"><p>0.067</p></td><td style="vertical-align:top"><p>0.071</p></td><td style="vertical-align:top"><p>0.076</p></td><td style="vertical-align:top"><p>0.080</p></td><td style="vertical-align:top"><p>0.084</p></td></tr><tr><td style="vertical-align:top"><p><strong>75</strong></p></td><td style="vertical-align:top"><p>0.032</p></td><td style="vertical-align:top"><p>0.036</p></td><td style="vertical-align:top"><p>0.041</p></td><td style="vertical-align:top"><p>0.045</p></td><td style="vertical-align:top"><p>0.050</p></td><td style="vertical-align:top"><p>0.054</p></td><td style="vertical-align:top"><p>0.059</p></td><td style="vertical-align:top"><p>0.063</p></td><td style="vertical-align:top"><p>0.068</p></td><td style="vertical-align:top"><p>0.072</p></td><td style="vertical-align:top"><p>0.077</p></td><td style="vertical-align:top"><p>0.081</p></td><td style="vertical-align:top"><p>0.086</p></td><td style="vertical-align:top"><p>0.090</p></td></tr><tr><td style="vertical-align:top"><p><strong>80</strong></p></td><td style="vertical-align:top"><p>0.034</p></td><td style="vertical-align:top"><p>0.038</p></td><td style="vertical-align:top"><p>0.043</p></td><td style="vertical-align:top"><p>0.048</p></td><td style="vertical-align:top"><p>0.053</p></td><td style="vertical-align:top"><p>0.058</p></td><td style="vertical-align:top"><p>0.062</p></td><td style="vertical-align:top"><p>0.067</p></td><td style="vertical-align:top"><p>0.072</p></td><td style="vertical-align:top"><p>0.077</p></td><td style="vertical-align:top"><p>0.082</p></td><td style="vertical-align:top"><p>0.086</p></td><td style="vertical-align:top"><p>0.091</p></td><td style="vertical-align:top"><p>0.096</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong><u>Administration by continuous intravenous infusion</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p>Trisuva is administered by continuous intravenous infusion via a central venous catheter, using an ambulatory infusion pump. It may also be administered temporarily via a peripheral venous cannula, preferably placed in a large vein. Use of a peripheral infusion for more than a few hours may be associated with an increased risk of thrombophlebitis (see section 4.8).</p><p>&nbsp;</p><p>When using an external infusion pump the patient must have access to a backup infusion pump and infusion sets in the event that the administration equipment malfunctions in order to avoid potential interruptions in drug delivery.</p><p>&nbsp;</p><p>In general, the ambulatory infusion pump used to administer diluted Trisuva intravenously should:</p><p>&nbsp;</p><p>1) be small and lightweight,</p><p>2) be capable of adjusting infusion rates in increments of approximately 0.05 ml/h.</p><p>3) have occlusion / no delivery, low battery, programming error and motor malfunction alarms,</p><p>4) have a maximal deviation of the adjusted flow rate of &plusmn;6% or better of the hourly dose</p><p>5) be positive pressure driven.</p><p>&nbsp;</p><p>The reservoir should be made of polyvinyl chloride, polypropylene or glass.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Trisuva should be diluted with either sterile Water for injection or 0.9% (w/v) Sodium chloride</strong></p><p><strong>for injection </strong>and is administered intravenously by continuous infusion, via a surgically placed indwelling central venous catheter or temporarily via a peripheral venous cannula, using an infusion pump designed for intravenous drug delivery.</p><p>&nbsp;</p><p>When using an appropriate infusion pump and reservoir, a predetermined intravenous infusion rate should first be selected to allow for a desired infusion period. The maximum duration of use of diluted Trisuva should be no more than 24 hours (see section 6.3)</p><p>&nbsp;</p><p>Typical intravenous infusion system reservoirs have volumes of 20, 50 or 100 ml. After determination of the required Intravenous Infusion Rate (ml/h) and the patient&rsquo;s dose (ng/kg/min) and weight (kg), the Diluted Intravenous treprostinil Concentration (mg/ml) can be calculated using the following formula:</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Step 1</u></strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Diluted&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose </strong>(ng/kg/min)&nbsp;&nbsp;&nbsp; <strong>x&nbsp;&nbsp;&nbsp;&nbsp; Weight </strong>(kg)&nbsp;&nbsp;&nbsp; <strong>x&nbsp;&nbsp;&nbsp;&nbsp; 0.00006</strong></p><p><strong>Intravenous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; = &nbsp;&nbsp;------------------------------------------------------------------</strong></p><p><strong>Treprostinil&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&nbsp; Intravenous Infusion Rate </strong>(ml/h)</p><p><strong>Concentration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p><p>(mg/ml)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>The amount of Trisuva needed to make the required Diluted Intravenous treprostinil concentration for the given reservoir size can then be calculated using the following formula:</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Step 2</u></strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diluted Intravenous</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treprostinil&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concentration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (mg/ml)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<strong>&nbsp;Total Volume of Diluted treprostinil</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amount of Trisuva&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;= &nbsp;&nbsp;----------------------------------&nbsp; x&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Solution in Reservoir&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;(ml)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Trisuva Vial Strength &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong>(ml)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (mg/ml)</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>The calculated amount of Trisuva is then added to the reservoir along with a sufficient volume of diluent (sterile Water for injection or 0.9% Sodium chloride for injection) to achieve the desired total volume in the reservoir.</p><p>&nbsp;</p><p>Example calculations for <strong><em>Intravenous Infusion </em></strong>are as follows:</p><p>&nbsp;</p><p><strong><u>Example 3:</u></strong></p><p>For a 60 kg person at a dose of 5 ng/kg/min, with a predetermined intravenous infusion rate of 1 ml/h and a reservoir of 50 ml, the Diluted Intravenous treprostinil solution Concentration would be calculated as follows:</p><p>&nbsp;</p><p><strong><u>Step 1</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong>Diluted</strong></p><p><strong>Intravenous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 </strong>ng/kg/min&nbsp;&nbsp; <strong>x&nbsp;&nbsp; 60 </strong>kg&nbsp;&nbsp; <strong>x&nbsp;&nbsp; 0.00006</strong></p><p><strong>Treprostinil&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; =&nbsp;&nbsp;&nbsp; ---------------------------------------------------&nbsp;&nbsp;&nbsp; = &nbsp;&nbsp;&nbsp;0.018 </strong>mg/ml</p><p><strong>Concentration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 </strong>ml/h&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(18,000 ng/ml)</p><p>(mg/ml)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>The amount of Trisuva (using 1 mg/ml Vial Strength) needed for a total Diluted treprostinil Concentration of 0.018 mg/ml and a total volume of 50 ml would be calculated as follows:</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Step 2</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Amount of Trisuva&nbsp;&nbsp;&nbsp;&nbsp; =&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.018 </strong>mg/ml&nbsp;&nbsp;&nbsp; x&nbsp;&nbsp; <strong>50 </strong>ml&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; =&nbsp;&nbsp; <strong>0.9 </strong>ml</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (ml)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ----------------------------------</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 mg/ml</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p>The Diluted Intravenous treprostinil Concentration for the person in Example 3 would thus be prepared by adding 0.9 ml of 1 mg/ml Trisuva to a suitable reservoir along with a sufficient volume of diluent to achieve a total volume of 50 ml in the reservoir. The pump flow rate for this example would be set at 1 ml/h.</p><p>&nbsp;</p><p><strong>Example 4:</strong></p><p>For a 75 kg person at a dose of 30 ng/kg/min, with a predetermined intravenous infusion rate of 2 ml/h, and a reservoir of 100 ml, the Diluted Intravenous treprostinil Solution Concentration would be calculated as follows:</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Step 1</u></strong></p><p>&nbsp;</p><p><strong>Diluted</strong></p><p><strong>Intravenous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30 </strong>ng/kg/min&nbsp; <strong>x&nbsp;&nbsp; 75 </strong>kg&nbsp;&nbsp; <strong>x&nbsp;&nbsp; 0.00006</strong></p><p><strong>Treprostinil&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; =&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -------------------------------------------------&nbsp;&nbsp;&nbsp; =&nbsp;&nbsp; 0.0675 mg/ml</strong></p><p><strong>Concentration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2mg/h</strong></p><p>(mg/ml)</p><p>The amount of Trisuva (using 2.5 mg/ml vial strength) needed for a total Diluted treprostinil Concentration of 0.0675 mg/ml and a total volume of 100 ml would be calculated as follows:</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Step 2</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.0675 </strong>mg/ml</p><p><strong>Amount of Trisuva&nbsp;&nbsp;&nbsp;&nbsp; =&nbsp;&nbsp; --------------------&nbsp;&nbsp;&nbsp;&nbsp; </strong>x&nbsp; 100 ml&nbsp; =&nbsp;&nbsp; 2.7 ml</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (ml)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 mg/ml</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>The Diluted Intravenous treprostinil Concentration for the person in Example 4 would thus be prepared by adding 2.7 ml of 2.5 mg/ml Trisuva to a suitable reservoir along with a sufficient volume of diluent to achieve a total volume of 100 ml in the reservoir. The pump flow rate for this example would be set at 2 ml/h.</p><p>&nbsp;</p><p>Table 2 provides guidance for the volume (ml) of Trisuva 10 mg/ml to be diluted in 20 ml, 50 ml or 100 ml reservoirs (0.4, 1 or 2 ml/h infusion rates, respectively) for patients of differing body weights corresponding to doses of up to 42.5 ng/kg/min.</p><p>&nbsp;</p><p>Table 2</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="17" style="vertical-align:top"><p><strong>Volume (ml) of Trisuva 5 mg/ml to be diluted in cassettes or syringes</strong></p><p><strong>20 ml (0.4 ml/h infusion rate), 50 ml (1 ml/h infusion rate), 100 ml cassette (2 ml/h infusion rate)</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Dose</strong></p><p><strong>(ng/</strong></p><p><strong>kg/</strong></p><p><strong>min)</strong></p></td><td colspan="16" style="vertical-align:top"><p><strong>Patient Weight (kg)</strong></p></td></tr><tr><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>55</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>70</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>85</p></td><td style="vertical-align:top"><p>90</p></td><td style="vertical-align:top"><p>95</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.150</p></td><td style="vertical-align:top"><p>0.180</p></td><td style="vertical-align:top"><p>0.210</p></td><td style="vertical-align:top"><p>0.240</p></td><td style="vertical-align:top"><p>0.270</p></td><td style="vertical-align:top"><p>0.300</p></td><td style="vertical-align:top"><p>0.330</p></td><td style="vertical-align:top"><p>0.360</p></td><td style="vertical-align:top"><p>0.390</p></td><td style="vertical-align:top"><p>0.420</p></td><td style="vertical-align:top"><p>0.450</p></td><td style="vertical-align:top"><p>0.480</p></td><td style="vertical-align:top"><p>0.510</p></td><td style="vertical-align:top"><p>0.540</p></td><td style="vertical-align:top"><p>0.570</p></td><td style="vertical-align:top"><p>0.600</p></td></tr><tr><td style="vertical-align:top"><p>12.5</p></td><td style="vertical-align:top"><p>0.188</p></td><td style="vertical-align:top"><p>0.225</p></td><td style="vertical-align:top"><p>0.263</p></td><td style="vertical-align:top"><p>0.300</p></td><td style="vertical-align:top"><p>0.338</p></td><td style="vertical-align:top"><p>0.375</p></td><td style="vertical-align:top"><p>0.413</p></td><td style="vertical-align:top"><p>0.450</p></td><td style="vertical-align:top"><p>0.488</p></td><td style="vertical-align:top"><p>0.525</p></td><td style="vertical-align:top"><p>0.563</p></td><td style="vertical-align:top"><p>0.600</p></td><td style="vertical-align:top"><p>0.638</p></td><td style="vertical-align:top"><p>0.675</p></td><td style="vertical-align:top"><p>0.713</p></td><td style="vertical-align:top"><p>0.750</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0.225</p></td><td style="vertical-align:top"><p>0.270</p></td><td style="vertical-align:top"><p>0.315</p></td><td style="vertical-align:top"><p>0.360</p></td><td style="vertical-align:top"><p>0.405</p></td><td style="vertical-align:top"><p>0.450</p></td><td style="vertical-align:top"><p>0.495</p></td><td style="vertical-align:top"><p>0.540</p></td><td style="vertical-align:top"><p>0.585</p></td><td style="vertical-align:top"><p>0.630</p></td><td style="vertical-align:top"><p>0.675</p></td><td style="vertical-align:top"><p>0.720</p></td><td style="vertical-align:top"><p>0.765</p></td><td style="vertical-align:top"><p>0.810</p></td><td style="vertical-align:top"><p>0.855</p></td><td style="vertical-align:top"><p>0.900</p></td></tr><tr><td style="vertical-align:top"><p>17.5</p></td><td style="vertical-align:top"><p>0.263</p></td><td style="vertical-align:top"><p>0.315</p></td><td style="vertical-align:top"><p>0.368</p></td><td style="vertical-align:top"><p>0.420</p></td><td style="vertical-align:top"><p>0.473</p></td><td style="vertical-align:top"><p>0.525</p></td><td style="vertical-align:top"><p>0.578</p></td><td style="vertical-align:top"><p>0.630</p></td><td style="vertical-align:top"><p>0.683</p></td><td style="vertical-align:top"><p>0.735</p></td><td style="vertical-align:top"><p>0.788</p></td><td style="vertical-align:top"><p>0.840</p></td><td style="vertical-align:top"><p>0.893</p></td><td style="vertical-align:top"><p>0.945</p></td><td style="vertical-align:top"><p>0.998</p></td><td style="vertical-align:top"><p>1.050</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>0.300</p></td><td style="vertical-align:top"><p>0.360</p></td><td style="vertical-align:top"><p>0.420</p></td><td style="vertical-align:top"><p>0.480</p></td><td style="vertical-align:top"><p>0.540</p></td><td style="vertical-align:top"><p>0.600</p></td><td style="vertical-align:top"><p>0.660</p></td><td style="vertical-align:top"><p>0.720</p></td><td style="vertical-align:top"><p>0.780</p></td><td style="vertical-align:top"><p>0.840</p></td><td style="vertical-align:top"><p>0.900</p></td><td style="vertical-align:top"><p>0.960</p></td><td style="vertical-align:top"><p>1.020</p></td><td style="vertical-align:top"><p>1.080</p></td><td style="vertical-align:top"><p>1.140</p></td><td style="vertical-align:top"><p>1.200</p></td></tr><tr><td style="vertical-align:top"><p>22.5</p></td><td style="vertical-align:top"><p>0.338</p></td><td style="vertical-align:top"><p>0.405</p></td><td style="vertical-align:top"><p>4.73</p></td><td style="vertical-align:top"><p>0.540</p></td><td style="vertical-align:top"><p>0.608</p></td><td style="vertical-align:top"><p>0.675</p></td><td style="vertical-align:top"><p>0.743</p></td><td style="vertical-align:top"><p>0.810</p></td><td style="vertical-align:top"><p>0.878</p></td><td style="vertical-align:top"><p>0.945</p></td><td style="vertical-align:top"><p>1.013</p></td><td style="vertical-align:top"><p>1.080</p></td><td style="vertical-align:top"><p>1.148</p></td><td style="vertical-align:top"><p>1.215</p></td><td style="vertical-align:top"><p>1.283</p></td><td style="vertical-align:top"><p>1.350</p></td></tr><tr><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>0.375</p></td><td style="vertical-align:top"><p>0.450</p></td><td style="vertical-align:top"><p>0.525</p></td><td style="vertical-align:top"><p>0.600</p></td><td style="vertical-align:top"><p>0.675</p></td><td style="vertical-align:top"><p>0.750</p></td><td style="vertical-align:top"><p>0.825</p></td><td style="vertical-align:top"><p>0.900</p></td><td style="vertical-align:top"><p>0.975</p></td><td style="vertical-align:top"><p>1.050</p></td><td style="vertical-align:top"><p>1.125</p></td><td style="vertical-align:top"><p>1.200</p></td><td style="vertical-align:top"><p>1.275</p></td><td style="vertical-align:top"><p>1.350</p></td><td style="vertical-align:top"><p>1.425</p></td><td style="vertical-align:top"><p>1.500</p></td></tr><tr><td style="vertical-align:top"><p>27.5</p></td><td style="vertical-align:top"><p>0.413</p></td><td style="vertical-align:top"><p>0.495</p></td><td style="vertical-align:top"><p>0.578</p></td><td style="vertical-align:top"><p>0.660</p></td><td style="vertical-align:top"><p>0.743</p></td><td style="vertical-align:top"><p>0.825</p></td><td style="vertical-align:top"><p>0.908</p></td><td style="vertical-align:top"><p>0.990</p></td><td style="vertical-align:top"><p>1.073</p></td><td style="vertical-align:top"><p>1.155</p></td><td style="vertical-align:top"><p>1.238</p></td><td style="vertical-align:top"><p>1.320</p></td><td style="vertical-align:top"><p>1.403</p></td><td style="vertical-align:top"><p>1.485</p></td><td style="vertical-align:top"><p>1.568</p></td><td style="vertical-align:top"><p>1.650</p></td></tr><tr><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>0.450</p></td><td style="vertical-align:top"><p>0.540</p></td><td style="vertical-align:top"><p>0.630</p></td><td style="vertical-align:top"><p>0.720</p></td><td style="vertical-align:top"><p>0.810</p></td><td style="vertical-align:top"><p>0.900</p></td><td style="vertical-align:top"><p>0.990</p></td><td style="vertical-align:top"><p>1.080</p></td><td style="vertical-align:top"><p>1.170</p></td><td style="vertical-align:top"><p>1.260</p></td><td style="vertical-align:top"><p>1.350</p></td><td style="vertical-align:top"><p>1.440</p></td><td style="vertical-align:top"><p>1.530</p></td><td style="vertical-align:top"><p>1.620</p></td><td style="vertical-align:top"><p>1.710</p></td><td style="vertical-align:top"><p>1.800</p></td></tr><tr><td style="vertical-align:top"><p>32.5</p></td><td style="vertical-align:top"><p>0.488</p></td><td style="vertical-align:top"><p>0.585</p></td><td style="vertical-align:top"><p>0.683</p></td><td style="vertical-align:top"><p>0.780</p></td><td style="vertical-align:top"><p>0.878</p></td><td style="vertical-align:top"><p>0.975</p></td><td style="vertical-align:top"><p>1.073</p></td><td style="vertical-align:top"><p>1.170</p></td><td style="vertical-align:top"><p>1.268</p></td><td style="vertical-align:top"><p>1.365</p></td><td style="vertical-align:top"><p>1.463</p></td><td style="vertical-align:top"><p>1.560</p></td><td style="vertical-align:top"><p>1.658</p></td><td style="vertical-align:top"><p>1.755</p></td><td style="vertical-align:top"><p>1.853</p></td><td style="vertical-align:top"><p>1.950</p></td></tr><tr><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>0.525</p></td><td style="vertical-align:top"><p>0.630</p></td><td style="vertical-align:top"><p>0.735</p></td><td style="vertical-align:top"><p>0.840</p></td><td style="vertical-align:top"><p>0.945</p></td><td style="vertical-align:top"><p>1.050</p></td><td style="vertical-align:top"><p>1.155</p></td><td style="vertical-align:top"><p>1.260</p></td><td style="vertical-align:top"><p>1.365</p></td><td style="vertical-align:top"><p>1.470</p></td><td style="vertical-align:top"><p>1.575</p></td><td style="vertical-align:top"><p>1.680</p></td><td style="vertical-align:top"><p>1.785</p></td><td style="vertical-align:top"><p>1.890</p></td><td style="vertical-align:top"><p>1.995</p></td><td style="vertical-align:top"><p>2.100</p></td></tr><tr><td style="vertical-align:top"><p>37.5</p></td><td style="vertical-align:top"><p>0.563</p></td><td style="vertical-align:top"><p>0.675</p></td><td style="vertical-align:top"><p>0.788</p></td><td style="vertical-align:top"><p>0.900</p></td><td style="vertical-align:top"><p>1.013</p></td><td style="vertical-align:top"><p>1.125</p></td><td style="vertical-align:top"><p>1.238</p></td><td style="vertical-align:top"><p>1.350</p></td><td style="vertical-align:top"><p>1.463</p></td><td style="vertical-align:top"><p>1.575</p></td><td style="vertical-align:top"><p>1.688</p></td><td style="vertical-align:top"><p>1.800</p></td><td style="vertical-align:top"><p>1.913</p></td><td style="vertical-align:top"><p>2.025</p></td><td style="vertical-align:top"><p>2.138</p></td><td style="vertical-align:top"><p>2.250</p></td></tr><tr><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>0.600</p></td><td style="vertical-align:top"><p>0.720</p></td><td style="vertical-align:top"><p>0.840</p></td><td style="vertical-align:top"><p>0.960</p></td><td style="vertical-align:top"><p>1.080</p></td><td style="vertical-align:top"><p>1.200</p></td><td style="vertical-align:top"><p>1.320</p></td><td style="vertical-align:top"><p>1.440</p></td><td style="vertical-align:top"><p>1.560</p></td><td style="vertical-align:top"><p>1.680</p></td><td style="vertical-align:top"><p>1.800</p></td><td style="vertical-align:top"><p>1.920</p></td><td style="vertical-align:top"><p>2.040</p></td><td style="vertical-align:top"><p>2.160</p></td><td style="vertical-align:top"><p>2.280</p></td><td style="vertical-align:top"><p>2.400</p></td></tr><tr><td style="vertical-align:top"><p>42.5</p></td><td style="vertical-align:top"><p>0.638</p></td><td style="vertical-align:top"><p>0.765</p></td><td style="vertical-align:top"><p>0.893</p></td><td style="vertical-align:top"><p>1.020</p></td><td style="vertical-align:top"><p>1.148</p></td><td style="vertical-align:top"><p>1.275</p></td><td style="vertical-align:top"><p>1.403</p></td><td style="vertical-align:top"><p>1.530</p></td><td style="vertical-align:top"><p>1.658</p></td><td style="vertical-align:top"><p>1.785</p></td><td style="vertical-align:top"><p>1.913</p></td><td style="vertical-align:top"><p>2.040</p></td><td style="vertical-align:top"><p>2.168</p></td><td style="vertical-align:top"><p>2.295</p></td><td style="vertical-align:top"><p>2.423</p></td><td style="vertical-align:top"><p>2.550</p></td></tr><tr><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>0.675</p></td><td style="vertical-align:top"><p>0.810</p></td><td style="vertical-align:top"><p>0.945</p></td><td style="vertical-align:top"><p>1.080</p></td><td style="vertical-align:top"><p>1.215</p></td><td style="vertical-align:top"><p>1.350</p></td><td style="vertical-align:top"><p>1.485</p></td><td style="vertical-align:top"><p>1.620</p></td><td style="vertical-align:top"><p>1.755</p></td><td style="vertical-align:top"><p>1.890</p></td><td style="vertical-align:top"><p>2.025</p></td><td style="vertical-align:top"><p>2.160</p></td><td style="vertical-align:top"><p>2.295</p></td><td style="vertical-align:top"><p>2.430</p></td><td style="vertical-align:top"><p>2.565</p></td><td style="vertical-align:top"><p>2.700</p></td></tr><tr><td style="vertical-align:top"><p>47.5</p></td><td style="vertical-align:top"><p>0.713</p></td><td style="vertical-align:top"><p>0.855</p></td><td style="vertical-align:top"><p>0.998</p></td><td style="vertical-align:top"><p>1.140</p></td><td style="vertical-align:top"><p>1.283</p></td><td style="vertical-align:top"><p>1.425</p></td><td style="vertical-align:top"><p>1.568</p></td><td style="vertical-align:top"><p>1.710</p></td><td style="vertical-align:top"><p>1.853</p></td><td style="vertical-align:top"><p>1.995</p></td><td style="vertical-align:top"><p>2.138</p></td><td style="vertical-align:top"><p>2.280</p></td><td style="vertical-align:top"><p>2.423</p></td><td style="vertical-align:top"><p>2.565</p></td><td style="vertical-align:top"><p>2.708</p></td><td style="vertical-align:top"><p>2.850</p></td></tr><tr><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>0.750</p></td><td style="vertical-align:top"><p>0.900</p></td><td style="vertical-align:top"><p>1.050</p></td><td style="vertical-align:top"><p>1.200</p></td><td style="vertical-align:top"><p>1.350</p></td><td style="vertical-align:top"><p>1.500</p></td><td style="vertical-align:top"><p>1.650</p></td><td style="vertical-align:top"><p>1.800</p></td><td style="vertical-align:top"><p>1.950</p></td><td style="vertical-align:top"><p>2.100</p></td><td style="vertical-align:top"><p>2.250</p></td><td style="vertical-align:top"><p>2.400</p></td><td style="vertical-align:top"><p>2.550</p></td><td style="vertical-align:top"><p>2.700</p></td><td style="vertical-align:top"><p>2.850</p></td><td style="vertical-align:top"><p>3.000</p></td></tr><tr><td style="vertical-align:top"><p>55</p></td><td style="vertical-align:top"><p>0.825</p></td><td style="vertical-align:top"><p>0.990</p></td><td style="vertical-align:top"><p>1.155</p></td><td style="vertical-align:top"><p>1.320</p></td><td style="vertical-align:top"><p>1.485</p></td><td style="vertical-align:top"><p>1.650</p></td><td style="vertical-align:top"><p>1.815</p></td><td style="vertical-align:top"><p>1.980</p></td><td style="vertical-align:top"><p>2.145</p></td><td style="vertical-align:top"><p>2.310</p></td><td style="vertical-align:top"><p>2.475</p></td><td style="vertical-align:top"><p>2.640</p></td><td style="vertical-align:top"><p>2.805</p></td><td style="vertical-align:top"><p>2.970</p></td><td style="vertical-align:top"><p>3.135</p></td><td style="vertical-align:top"><p>3.300</p></td></tr><tr><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>0.900</p></td><td style="vertical-align:top"><p>1.080</p></td><td style="vertical-align:top"><p>1.260</p></td><td style="vertical-align:top"><p>1.440</p></td><td style="vertical-align:top"><p>1.620</p></td><td style="vertical-align:top"><p>1.800</p></td><td style="vertical-align:top"><p>1.980</p></td><td style="vertical-align:top"><p>2.160</p></td><td style="vertical-align:top"><p>2.340</p></td><td style="vertical-align:top"><p>2.520</p></td><td style="vertical-align:top"><p>2.700</p></td><td style="vertical-align:top"><p>2.880</p></td><td style="vertical-align:top"><p>3.060</p></td><td style="vertical-align:top"><p>3.240</p></td><td style="vertical-align:top"><p>3.420</p></td><td style="vertical-align:top"><p>3.600</p></td></tr><tr><td style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>0.975</p></td><td style="vertical-align:top"><p>1.170</p></td><td style="vertical-align:top"><p>1.365</p></td><td style="vertical-align:top"><p>1.560</p></td><td style="vertical-align:top"><p>1.755</p></td><td style="vertical-align:top"><p>1.950</p></td><td style="vertical-align:top"><p>2.145</p></td><td style="vertical-align:top"><p>2.340</p></td><td style="vertical-align:top"><p>2.535</p></td><td style="vertical-align:top"><p>2.730</p></td><td style="vertical-align:top"><p>2.925</p></td><td style="vertical-align:top"><p>3.120</p></td><td style="vertical-align:top"><p>3.315</p></td><td style="vertical-align:top"><p>3.510</p></td><td style="vertical-align:top"><p>3.705</p></td><td style="vertical-align:top"><p>3.900</p></td></tr><tr><td style="vertical-align:top"><p>70</p></td><td style="vertical-align:top"><p>1.050</p></td><td style="vertical-align:top"><p>1.260</p></td><td style="vertical-align:top"><p>1.470</p></td><td style="vertical-align:top"><p>1.680</p></td><td style="vertical-align:top"><p>1.890</p></td><td style="vertical-align:top"><p>2.100</p></td><td style="vertical-align:top"><p>2.310</p></td><td style="vertical-align:top"><p>2.520</p></td><td style="vertical-align:top"><p>2.730</p></td><td style="vertical-align:top"><p>2.940</p></td><td style="vertical-align:top"><p>3.150</p></td><td style="vertical-align:top"><p>3.360</p></td><td style="vertical-align:top"><p>3.570</p></td><td style="vertical-align:top"><p>3.780</p></td><td style="vertical-align:top"><p>3.990</p></td><td style="vertical-align:top"><p>4.200</p></td></tr><tr><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>1.125</p></td><td style="vertical-align:top"><p>1.350</p></td><td style="vertical-align:top"><p>1.575</p></td><td style="vertical-align:top"><p>1.800</p></td><td style="vertical-align:top"><p>2.025</p></td><td style="vertical-align:top"><p>2.250</p></td><td style="vertical-align:top"><p>2.475</p></td><td style="vertical-align:top"><p>2.700</p></td><td style="vertical-align:top"><p>2.925</p></td><td style="vertical-align:top"><p>3.150</p></td><td style="vertical-align:top"><p>3.375</p></td><td style="vertical-align:top"><p>3.600</p></td><td style="vertical-align:top"><p>3.825</p></td><td style="vertical-align:top"><p>4.050</p></td><td style="vertical-align:top"><p>4.275</p></td><td style="vertical-align:top"><p>4.500</p></td></tr><tr><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>1.200</p></td><td style="vertical-align:top"><p>1.440</p></td><td style="vertical-align:top"><p>1.680</p></td><td style="vertical-align:top"><p>1.920</p></td><td style="vertical-align:top"><p>2.160</p></td><td style="vertical-align:top"><p>2.400</p></td><td style="vertical-align:top"><p>2.640</p></td><td style="vertical-align:top"><p>2.880</p></td><td style="vertical-align:top"><p>3.120</p></td><td style="vertical-align:top"><p>3.360</p></td><td style="vertical-align:top"><p>3.600</p></td><td style="vertical-align:top"><p>3.840</p></td><td style="vertical-align:top"><p>4.080</p></td><td style="vertical-align:top"><p>4.320</p></td><td style="vertical-align:top"><p>4.560</p></td><td style="vertical-align:top"><p>4.800</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Training for patients receiving a continuous intravenous infusion</u></p><p>The clinical team responsible for the therapy must ensure that the patient is fully trained and competent to use the chosen infusion device. A period of personal instruction and supervision should continue until the patient is judged competent to change infusions, alter flow rates/doses as instructed, and be able to deal with common device alarms. Patients must be trained in proper aseptic technique when preparing the Trisuva infusion reservoir and priming the infusion delivery tubing and connection. Written guidance, either from the pump manufacturer or a specifically tailored advice by the prescribing physician, must be made available to the patient. This would include the required normal drug delivery actions, advice on how to manage occlusions and other pump alarms, and details of whom to contact in an emergency.</p><p>&nbsp;</p><p><strong>Minimising the risk of catheter-related blood stream infections &ndash; CR-BSI</strong></p><p><strong>&nbsp;</strong></p><p>Particular attention must be given to the following to help minimise the risk of catheter related blood stream infections in patients that are receiving treprostinil via intravenous infusion (see section 4.4).</p><p>This advice is in accordance with the current best practice guidelines for the prevention of catheterrelated blood stream infections, and includes:</p><p>&nbsp;</p><p><em>General principles</em></p><p><em>&nbsp;</em></p><p>- Use of a cuffed and tunnelled central venous catheter (CVC) with a minimum number of ports.</p><p>- insertion of the CVC using sterile barrier techniques.</p><p>- use of proper hand hygiene and aseptic techniques when the catheter is inserted, replaced, accessed, or repaired or when the catheter insertion site is examined and/or dressed.</p><p>- a sterile gauze (replaced every other day) or a sterile, semi-permeable dressing (replaced at least every seven days) should be used to cover the catheter insertion site.</p><p>- the dressing should be replaced whenever it becomes damp, loosened, or soiled or after examination of the site</p><p>- Topical antibiotic ointments or creams should not be applied, as they may promote fungal infections and antimicrobial-resistant bacteria.</p><p>&nbsp;</p><p><em>Duration of use of diluted Trisuva solution</em></p><p><em>&nbsp;</em></p><p>- the maximum duration of use of the diluted product should be no more than 24 hours.&nbsp;<em>Use of in-line 0.2 micron filter</em></p><p>- a 0.2 micron filter must be placed between the infusion tubing and the catheter hub and replaced every 24 hours at the time of changing the infusion reservoir</p><p>&nbsp;</p><p>Two further recommendations that are potentially important for the prevention of water-borne Gram negative blood stream infections, relate to management of the catheter hub. These include:</p><p>&nbsp;</p><p><em>Use of a split-septum closed hub system</em></p><p><em>&nbsp;</em></p><p>- the use of a closed-hub system (preferably with a split septum rather than a mechanical valve device), ensures that the lumen of the catheter is sealed each time the infusion system is disconnected. This prevents the risk of exposure to microbial contamination;</p><p>- the split-septum closed-hub device should be replaced every 7 days.</p><p>&nbsp;</p><p><em>Infusion system luer-lock inter-connections</em></p><p><em>&nbsp;</em></p><p>The risk of contamination with water-borne Gram-negative organisms is likely to be increased if a luerlock inter-connection is wet at the time of exchanging either the infusion line or the closed hub</p><p>Therefore:</p><p>&nbsp;</p><p>- swimming and submersion of the infusion system at the site of connection with the catheter hub should be discouraged</p><p>- at the time of replacing the closed-hub device there should not be any water visible in the Luer- Lock connection threads</p><p>- the infusion line should only be disconnected from the closed hub device once every 24 hours at the time of replacement.</p><p>&nbsp;</p><p>For special handling instructions see Section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Pulmonary arterial hypertension related to veno-occlusive disease.
- Congestive heart failure due to severe left ventricular dysfunction.
- Severe liver impairment (Child-Pugh Class C).
- Active gastrointestinal ulcer, intracranial haemorrhage, injury or other bleeding condition.
- Congenital or acquired valvular defects with clinically relevant myocardial dysfunction not related to pulmonary hypertension.
- Severe coronary heart disease or unstable angina; myocardial infarction within the last six months;
decompensated cardiac failure if not under close medical supervision; severe arrhythmias;
cerebrovascular events (e.g. transient ischaemic attack, stroke) within the last three months.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The decision to initiate therapy with treprostinil should take into consideration the high probability that a continuous infusion will have to be continued for a prolonged period. Thus the patient&#39;s ability to accept and to be responsible for an indwelling catheter and infusion device should be carefully considered.</p><p>&nbsp;</p><p>Treprostinil is a potent pulmonary and systemic vasodilator. In subjects presenting with low systemic arterial pressure, treprostinil treatment may increase the risk of systemic hypotension. Treatment is not recommended for patients with systolic arterial pressure of less than 85 mmHg.</p><p>&nbsp;</p><p>It is recommended to monitor systemic blood pressure and heart rate during any change in dose with instructions to stop the infusion if symptoms of hypotension develop, or a systolic blood pressure of 85 mmHg or lower is detected.</p><p>&nbsp;</p><p>Abrupt withdrawal or sudden marked reductions in the dose of treprostinil may cause a rebound in pulmonary arterial hypertension (see section 4.2).</p><p>&nbsp;</p><p>If a patient contracts pulmonary oedema while on treprostinil, the possibility of an associated pulmonary veno-occlusive disease should be considered. The treatment should be stopped.</p><p>&nbsp;</p><p>Obese patients (BMI greater than 30 kg/m2) clear treprostinil more slowly.</p><p>&nbsp;</p><p>The benefit of treprostinil subcutaneous treatment in patients with pulmonary arterial hypertension (NYHA functional class IV) has not been established.</p><p>&nbsp;</p><p>The efficacy/safety ratio of treprostinil has not been studied in pulmonary arterial hypertension associated with left-right cardiac shunt, portal hypertension, or HIV infection.</p><p>&nbsp;</p><p>Patients with hepatic and renal impairment should be dosed cautiously (see section 4.2).</p><p>&nbsp;</p><p>As treprostinil and its metabolites are excreted mainly through the urinary route, caution is recommended when treating patients with renal impairment in order to prevent deleterious consequences related to the possible increase of systemic exposure (see section 4.2).</p><p>&nbsp;</p><p>Caution is advised in situations where treprostinil may increase the risk of bleeding by inhibiting platelet aggregation.</p><p>&nbsp;</p><p>Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g. gemfibrozil) may increase exposure (both Cmax and AUC) to treprostinil. Increased exposure is likely to increase adverse events associated with treprostinil administration. Treprostinil dose reduction should be considered (see section 4.5).</p><p>&nbsp;</p><p>Co-administration of a CYP2C8 enzyme inducer (e.g. rifampicin) may decrease exposure to treprostinil.</p><p>Decreased exposure is likely to reduce clinical effectiveness. Treprostinil dose increase should be considered (see section 4.5).</p><p>&nbsp;</p><p>This medicinal product contains a maximum of 39.1 mg sodium per 5 mg/vial, equivalent to 2% of the WHO recommended maximum daily intake of 2g sodium for an adult.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Adverse events attributable to the intravenous drug delivery system</u></p><p>&nbsp;</p><p>Central venous catheter associated blood stream infections and sepsis have been reported in patients receiving treprostinil by intravenous infusion. These risks are attributable to the drug delivery system.</p><p>A US Center for Disease Control retrospective survey of seven centres in the United States that used intravenous treprostinil for the treatment of PAH found an incidence rate for catheter-related</p><p>bloodstream infections of 1.10 events per 1000 catheter days. Clinicians should be aware of the range of possible Gram-negative and Gram-positive organisms that may infect patients with long-term central venous catheters. Therefore, continuous subcutaneous infusion of undiluted Trisuva is the preferred mode of administration.</p><p>&nbsp;</p><p>The clinical team responsible for the therapy must ensure that the patient is fully trained and competent to use the chosen infusion device (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Associations to consider</u></p><p><u>&nbsp;</u></p><p>+ <em>Diuretics, antihypertensive agents, or other vasodilators</em></p><p><em>&nbsp;</em></p><p>Concomitant administration of treprostinil with diuretics, antihypertensive agents or other vasodilators increases the risk of systemic hypotension.</p><p>&nbsp;</p><p>+ <em>Platelet aggregation inhibitors, including NSAIDs and anticoagulants</em></p><p><em>&nbsp;</em></p><p>Treprostinil may inhibit platelet function. Concomitant administration of treprostinil with platelet aggregation inhibitors<strong><em>, </em></strong>including NSAIDs, nitric oxide donors or anticoagulants may increase the risk of bleeding. Surveillance of patients taking anticoagulants should be closely maintained in accordance with conventional medical practice recommendations when monitoring such treatments. The concomitant use of other platelet inhibitors should be avoided in patients taking anticoagulants.</p><p>Continuous subcutaneous infusion of treprostinil had no effect on pharmacodynamics and pharmacokinetics of a single dose (25 mg) of warfarin. There are no data available on the potential interactions leading to increased risk of bleeding if treprostinil is co-prescribed with nitric oxide donors<strong><em>.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong>+ </strong><em>Furosemide</em></p><p><em>&nbsp;</em></p><p>Treprostinil plasma clearance may be slightly reduced in patients treated with furosemide. This interaction is probably due to some common metabolic features shared by both compounds (carboxylate group glucuroconjugation).</p><p>&nbsp;</p><p><strong>+ </strong><em>Cytochrome P450 (CYP) 2C8 enzyme inducers/inhibitors</em></p><p><em>&nbsp;</em></p><p><em>Gemfibrozil </em>&ndash; Human pharmacokinetic studies with oral treprostinil diolamine indicated that coadministration of cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil doubles the exposure (both Cmax and AUC) to treprostinil. It has not been determined if the safety and efficacy of treprostinil by the parenteral (subcutaneous or intravenous) route are altered by inhibitors of CYP2C8. If a CYP2C8 inhibitor (e.g. gemfibrozil, trimethoprim and deferasirox) is added to or subtracted from the patient&rsquo;s medications after the titration period, treprostinil dose adjustment should be considered.</p><p>&nbsp;</p><p><em>Rifampicin </em>- Human pharmacokinetic studies with oral treprostinil diolamine indicated that coadministration of the CYP2C8 enzyme inducer rifampicin decreases exposure to treprostinil (by approximately 20%). It has not been determined if the safety and efficacy of treprostinil by the parenteral (subcutaneous or intravenous) route are altered by rifampicin. If rifampicin is added to or subtracted from the patient&rsquo;s medications after the titration period, treprostinil dose adjustment should be considered.</p><p>&nbsp;</p><p>CYP2C8 inducers (e.g. phenytoin, carbamazepine, phenobarbital and St. John&#39;s Wort) may reduce the exposure to treprostinil. If a CYP2C8 inducer is added to or subtracted from the patient&rsquo;s medications after the titration period, treprostinil dose adjustment should be considered.</p><p>&nbsp;</p><p><strong>+ </strong><em>Bosentan</em></p><p><em>&nbsp;</em></p><p>In a human pharmacokinetic study conducted with bosentan (250 mg/day) and treprostinil diolamine (oral dose 2 mg/day), no pharmacokinetic interactions between treprostinil and bosentan were observed.</p><p>&nbsp;</p><p><strong>+ </strong><em>Sildenafil</em></p><p><em>&nbsp;</em></p><p>In a human pharmacokinetic study conducted with sildenafil (60 mg/day) and treprostinil diolamine (oral dose 2 mg/day), no pharmacokinetic interactions</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>No adequate data on the use of treprostinil in pregnant women are available. Animal studies are insufficient with respect to effects on pregnancy (see section 5.3). The potential risk for humans is unknown. Treprostinil should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the foetus.</p><p>&nbsp;</p><p><em>Women of child-bearing potential</em>&nbsp;Contraception is recommended during treprostinil treatment.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>&nbsp;</p><p>It is not known whether treprostinil is excreted in human milk. Breastfeeding women using treprostinil should be advised to discontinue breastfeeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Trisuva has a mild influence on the ability to drive and to use machines.</p><p>&nbsp;</p><p>The initiation of treatment or dosage adjustments may be accompanied by undesirable effects such as symptomatic systemic hypotension or dizziness, which may impair the ability to drive and operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions observed in placebo-controlled studies and post-marketing experience with treprostinil are ranked according to frequency using the following convention:</p><p>very common (&ge;1/10);</p><p>common (&ge;1/100 to &lt; 1/10);</p><p>uncommon (&ge;1/1,000 to &lt; 1/100);</p><p>rare (&ge;1/10,000 to &lt; 1/1,000);</p><p>very rare (&lt; 1/10,000);</p><p>not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>High output cardiac failure</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Vasodilatation, flushing</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Bleeding event&sect;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Thrombophlebitis*</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Diarrhoea, nausea</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Generalised rashes (macular or papular in</p><p>nature)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Musculoskeletal, connective</strong></p><p><strong>tissue and bone disorders</strong></p></td><td style="vertical-align:top"><p>Jaw pain</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia, arthralgia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Bone pain</p></td><td style="vertical-align:top"><p>Not known</p></td></tr></tbody></table><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>General disorders and</strong></p><p><strong>administration site conditions</strong></p></td><td style="vertical-align:top"><p>Infusion site pain, infusion site reaction,</p><p>bleeding or haematoma.</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Oedema</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>Central venous catheter-associated blood</p><p>stream infection, sepsis, bacteraemia<strong>**</strong></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Infusion site infection, subcutaneous</p><p>infusion site abscess formation</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Cellulitis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p>* Cases of thrombophlebitis associated with peripheral intravenous infusion have been reported</p><p><strong>** Life-threatening and fatal cases have been reported</strong></p><p>&sect; See section &laquo;Description of selected adverse events&raquo;</p><p><u>Description of selected adverse events</u></p><p><u>&nbsp;</u></p><p><em>Bleeding events</em></p><p><em>&nbsp;</em></p><p>Bleeding events were common as expected in this patient population with a high proportion of patients treated with anticoagulants. Due to its effects on platelet aggregation, treprostinil may increase the risk of bleeding, as observed by an increased incidence of epistaxis and gastrointestinal (GI) bleeding (including gastrointestinal haemorrhage, rectal haemorrhage, gum haemorrhage and melaena) in controlled clinical trials. There were also reports of haemoptysis, haematemesis and haematuria, but these occurred with the same or lower frequency than in the placebo group.</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system:</p><p>&nbsp;</p><p>Bundesamt f&uuml;r Sicherheit im Gesundheitswesen</p><p>Traisengasse 5</p><p>1200 VIENNA</p><p>AUSTRIA</p><p>Fax: + 43 (0) 50 555 36207</p><p>Website: http://www.basg.gv.at/</p><p>&nbsp;</p><p>Saudi-Arabia:</p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-Mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms of overdose with Trisuva are similar to the effects of dose increases; they include flushing,&nbsp; headache, hypotension, nausea, vomiting, and diarrhoea. Patients experiencing symptoms of overdose should immediately reduce or discontinue their dose of treprostinil depending on the severity of the symptoms until the symptoms of overdose have resolved. Dosing should be recommenced with caution under medical control and patients monitored closely for recurrence of unwanted symptoms.</p><p>&nbsp;</p><p>No antidote is known.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: PLATELET AGGREGATION INHIBITORS, EXCLUDING HEPARIN,</p><p>ATC code: B01AC21</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Treprostinil is a prostacyclin analogue.</p><p>It exerts a direct vasodilation effect on the pulmonary and systemic arterial circulation and, inhibits platelet aggregation.</p><p>&nbsp;</p><p>In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. The effect of treprostinil on the heart rate in animals varies with the dose. No major effects on cardiac conduction have been observed.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><strong>Data on efficacy in adults with pulmonary arterial hypertension:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Studies with subcutaneously administered treprostinil</strong></p><p><strong>&nbsp;</strong></p><p>Two phase III randomised, double-blind, placebo-controlled clinical trials have been conducted with treprostinil administered by subcutaneous continuous infusion in subjects with stable pulmonary arterial hypertension.</p><p>A total of 469 adults were included in the two trials: 270 presented with idiopathic or heritable pulmonary arterial hypertension (treprostinil group = 134 patients; placebo group = 136 patients), 90 patients presented with pulmonary arterial hypertension associated with connective tissue disease (mainly scleroderma) (treprostinil group = 41 patients; placebo group = 49 patients) and 109 patients presented with pulmonary arterial hypertension associated with congenital cardiopathy with left-right shunt (treprostinil = 58 patients; placebo = 51 patients).</p><p>At baseline, the mean 6-minute walking test distance was 326 metres + 5 in the group receiving treprostinil through subcutaneous infusion and 327 metres + 6 in the group receiving placebo. The dose of both treatments being compared was progressively increased during the study according to pulmonary arterial hypertension symptoms and clinical tolerance. The mean dose achieved after 12 weeks was 9.3 ng/kg/min in the treprostinil group and 19.1 ng/kg/min in the placebo group. After 12 weeks of treatment, the mean variation in the 6-minute walk test compared to baseline, calculated on the global population from both trials, was -2 metres &plusmn; 6.61 metres in the patients receiving treprostinil and -21.8 metres &plusmn; 6.18 metres in the placebo group. These results reflected a mean treatment effect assessed by the 6-minute walk test of 19.7 metres (p = 0.0064) compared to placebo for the global population from both trials.</p><p>&nbsp;</p><p>Mean changes compared to baseline values in haemodynamic parameters (mean pulmonary arterial pressure (PAPm)), right atrial pressure (RAP), pulmonary vascular resistance (PVR), cardiac index (CI) and venous oxygen saturation (SvO2) showed treprostinil to be superior to placebo. The improvement in signs and symptoms of pulmonary hypertension (syncope, dizziness, chest pain, fatigue and dyspnoea) was statistically significant (p&lt; 0.0001). In addition, the Dyspnoea-Fatigue Rating and Borg Dyspnoea Score were improved in patients treated with treprostinil after 12 weeks (p&lt; 0.0001).</p><p>Analysis of a combined criterion associating the improvement of exercise capacity (6-minute walk test) of at least 10% compared to baseline after 12 weeks, an improvement by at least one NYHA class compared to baseline after 12 weeks and absence of deterioration in pulmonary hypertension together with a lack of death reported before week 12 for the global population of both studies showed the number of subjects responding to treprostinil to be 15.9% (37/233) while only 3.4% (8/236) of subjects in the placebo group responded. Sub-group analysis of the global population showed a statistically significant treatment effect of treprostinil compared to placebo on the 6-minute walk test in the sub-population of subjects with idiopathic or heritable pulmonary arterial hypertension (p=0.043) but not in the sub-population of subjects with pulmonary arterial hypertension associated with scleroderma or congenital cardiopathy.</p><p>&nbsp;</p><p>The effect seen on the primary endpoint (i.e., change in six minute walk distance after 12 weeks of treatment) was smaller than that seen in historical controls with bosentan, iloprost and epoprostenol.</p><p>No study directly comparing treprostinil and epoprostenol intravenous infusion has been conducted.</p><p>&nbsp;</p><p>No specific study has been conducted in children with PAH.</p><p>&nbsp;</p><p>There are no data from clinical studies conducted with an active comparator in patients with PAH.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Resorption and distribution</u></p><p>In humans, steady-state plasma concentrations are usually achieved within 15 to 18 hours of the initiation of either subcutaneous or intravenous infusion of treprostinil. Steady-state plasma concentrations of treprostinil are dose-proportional at infusion rates of 2.5 up to 125 ng/kg/min.</p><p>Subcutaneous and intravenous administration of treprostinil demonstrated bioequivalence at steady state at a dose of 10 ng/kg/min.</p><p>&nbsp;</p><p>In a seven-day uninterrupted chronic pharmacokinetic study in 14 healthy volunteers with treprostinil doses ranging from 2.5 to 15 ng/kg/min administered by subcutaneous infusion, steady state plasma treprostinil concentrations reached peak levels twice (at 1 a.m. and 10 a.m. respectively) and trough levels twice (at 7 a.m. and 4 p.m. respectively). The peak concentrations were approximately 20% to 30% higher than the trough concentrations.</p><p>&nbsp;</p><p><u>Biotransformation and elimination</u></p><p>The mean apparent elimination half-life following subcutaneous administration ranged from 1.32 to 1.42 hours after infusions over 6 hours, 4.61 hours after infusions over 72 hours, and 2.93 hours after infusions lasting at least three weeks. The mean volume of distribution for treprostinil ranged from 1.11 to 1.22 l/kg, and plasma clearance ranged from 586.2 to 646.9 ml/kg/h. Clearance is lower in obese subjects (BMI &gt; 30 kg/m2).</p><p>&nbsp;</p><p>In a study conducted on healthy volunteers using [14C] radioactive treprostinil, 78.6% and 13.4% of the subcutaneous radioactive dose were recovered in the urine and faeces respectively over a period of 224 hours. No single major metabolite was observed. Five metabolites were detected in the urine, ranging from 10.2% to 15.5% of the dose administered. These five metabolites accounted for a combined total of 64.4%. Three are products of oxidation of the 3-hydroxyloctyl side chain, one is a glucuro-conjugated derivative (treprostinil glucuronide) and one is unidentified. Only 3.7% of the dose was recovered in the urine as unchanged parent drug.</p><p>&nbsp;</p><p>An <em>in vitro </em>study demonstrated no inhibitory potential of treprostinil to human hepatic microsomal cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A).</p><p>&nbsp;</p><p>Moreover, administration of treprostinil had no inducing effect on hepatic microsomal protein, total cytochrome (CYP) P 450 content or on the activities of the isoenzymes CYP1A, CYP2B and CYP3A.</p><p>&nbsp;</p><p>Clinical drug interaction studies have been carried out with paracetamol (4 g/day) and warfarin (25 mg/day) in healthy volunteers. These studies did not show a clinically significant effect on the pharmacokinetics of treprostinil. A study conducted with warfarin found no apparent pharmacodynamic nor pharmacokinetic interaction between treprostinil and warfarin.</p><p>&nbsp;</p><p>The metabolism of treprostinil mainly involves CYP2C8.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Special populations</strong></p><p><strong>&nbsp;</strong></p><p><em>Hepatic impairment</em>:</p><p>In patients with portopulmonary hypertension and mild (n=4) or moderate (n=5) hepatic insufficiency, treprostinil at a subcutaneous dose of 10 ng/kg/min for 150 minutes had an AUC0-24 h that was increased 260% and 510%, respectively, compared to healthy subjects. Clearance in patients with hepatic insufficiency was reduced by up to 80% compared to healthy adults (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In 13 and 26 week studies continuous subcutaneous infusions of treprostinil sodium caused infusion site reactions in rats and dogs (oedema/erythema, masses/swellings, pain/sensitivity to touch). In dogs severe clinical effects (hypoactivity, emesis, loose stool and infusion site oedema) and death (associated with intestinal intussusceptions and rectal prolapse) were observed in animals administered &ge; 300 ng/kg/min.</p><p>Mean steady state plasma treprostinil levels of 7.85 ng/ml were measured in these animals. Plasma levels of this order may be achieved in humans treated with treprostinil infusions at &gt; 50 ng/kg/min.</p><p>&nbsp;</p><p>As a continuously sufficient exposure to treprostinil has not been proven for any dosage tested in the reproductive studies in rats, these studies might be insufficient regarding possible effects on fertility, prenatal and postnatal development.</p><p>&nbsp;</p><p>No long-term animal studies have been performed to evaluate treprostinil&rsquo;s carcinogenic potential. <em>In vitro </em>and <em>in vivo </em>genotoxicity studies did not show treprostinil to have any mutagenic or clastogenic effect.</p><p>&nbsp;</p><p>In summary, preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and toxicity to reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Metacresol</p><p>Sodium citrate (dihydrate)</p><p>Sodium chloride</p><p>Hydrochloric acid</p><p>Sodium hydroxide</p><p>Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No compatibility studies having been carried out, this medicinal product must not be mixed with other medicinal products except those mentioned in Section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life of the medicinal product as packaged for sale: 3 years

Shelf-life of vial after first opening: 30 days at 30 °C maximum

Shelf life during continuous subcutaneous infusion
The chemical, physical and microbiological in-use stability of a single reservoir (syringe) of undiluted treprostinil administered via subcutaneous infusion could be established at 37°C for up to 14 days. Other storage times and conditions after first opening fall to the responsibility of the user.

Shelf life during continuous intravenous infusion
The chemical, physical and microbiological in-use stability of a single container (syringe) of diluted treprostinil solution administered via intravenous infusion could be established at 37°C for up to 24 hours. Other storage times and conditions after first opening fall to the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p><p>&nbsp;</p><p>See section 6.3 for in-use storage times and conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 ml solution for infusion in a 10 ml borosilicate type I clear glass vial sealed with stoppers made of chlorobutyl-blended rubber with fluoropolymer coating secured with an aluminium flip-off crimp with a green-coloured polypropylene cap.</p><p>&nbsp;</p><p>Each carton contains one vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Trisuva should be used <strong>undiluted</strong>, if it is administered via continuous subcutaneous infusion (see section 4.2).</p><p>&nbsp;</p><p>Trisuva <strong>should be </strong>diluted with either sterile Water for injection or 0.9% (w/v) Sodium chloride for injection, if it is administered via continuous intravenous infusion (see section 4.2).</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AOP Orphan Pharmaceuticals GmbH
Leopold-Ungar-Platz 2
A-1190 Wien

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>